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Abstract 
 
 Genetic alterations resulting in uncontrolled protein tyrosine kinases (PTKs) 
activity are frequently found in leukemia and in human solid cancers. Although the 
development of small molecule kinase inhibitors has revolutionized therapy for PTK-
induced chronic myeloid leukemia, their effect is limited in cancers with several 
genetic alterations and increased multi-factorial drug resistance is hampering 
therapies. To overcome these limitations, it is indispensable to identify essential 
targets acting downstream of an oncogenic PTK.  
 FLT3-ITD mediated leukemogenesis is associated with increased expression 
of oncogenic PIM serine/threonine kinases. To dissect their role in FLT3-ITD-
mediated transformation, we performed bone marrow reconstitution assays. 
Unexpectedly, FLT3-ITD cells deficient for PIM1 failed to reconstitute lethally 
irradiated recipients whereas lack of PIM2 induction did not interfere with FLT3-ITD-
induced disease. PIM1-deficient bone marrow showed defects in homing and 
migration and displayed decreased surface CXCR4 expression and impaired 
CXCL12/CXCR4 signaling. Through siRNA-mediated knockdown, chemical 
inhibition, expression of a dominant negative mutant or and re-expression in 
knockout cells we found PIM1 activity to be essential for proper CXCR4 surface 
expression and migration of cells towards a CXCL12 gradient. PIM1 directly 
phosphorylated Serine 339, a residue in the CXCR4 intracellular domain essential for 
normal receptor recycling. In primary leukemic blasts high levels of surface CXCR4 
were associated with increased PIM1 expression, and could be significantly reduced 
by a small molecule PIM inhibitor in some patients. Our data suggest that PIM1 
activity is essential for homing and migration of hematopoietic cells through direct 
modification of CXCR4. Since CXCR4 is also important for homing and maintenance 
of cancer stem cells, PIM1 inhibitors may exert their anti-tumor effects in part by 
interfering with interactions with the microenvironment. We extensively tested 
different classes of PIM inhibitors and could show that some of these compounds 
could impair survival and growth of different hematopoietic cellular systems, including 
blasts from AML patients. 
 The second goal of my thesis was to create a mouse model for a PTK-fusion 
gene, NUP214/ABL1, associated with human T-cell acute leukemia. We generated 
two transgenic lines expressing the NUP214/ABL1 fusion from a T-cell linked (lck) 
promoter. However, no phenotype was observed after more than one year. Further 
experiments are ongoing to analyze whether co-expression of putative collaborating 
oncogenes, associated in human T-cell leukemia, such as HOX11/HX11L2 is able 
toinduce or respectively accelerate leukemogenesis. 
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 I. Introduction 
 
 
1. Cancer 
 
 Research of the last century has generated a rich and complex body of 
knowledge, revealing cancer to be a disease involving dynamic changes in the 
genome. The foundation has been set by the discovery of mutations producing 
oncogenes with dominant gain of function alterations and tumor suppressor genes 
with recessive loss of function alterations. Both classes of cancer genes have been 
identified through their alterations in human and animal cancer cells and by their 
elicitation of cancer phenotypes in experimental models. Several lines of evidence 
indicate that tumorigenesis in human is a multi-step process and that these steps 
reflect genetic alterations that drive a progressive transformation of normal human 
cells into highly malignant derivatives (Hanahan, 2000).  
 These observations became more concrete by extensive experimental work 
indicating that the genomes of tumor cells are invariably altered at multiple sites, 
having suffered disruption through lesions as subtle as point mutations and as 
obvious as changes in chromosome complement. Transgenic models of 
tumorigenesis have repeatedly supported the conclusion that tumorigenesis in mice 
involves multiple rate-limiting steps (Bergers, 1998).  Taken together, observations 
of human cancers and animal models argue that tumor development proceeds via a 
process formally analogous to Darwinian evolution, in which a succession of genetic 
changes, each conferring one or another types of selective advantage, leads to the 
progressive conversion of normal into cancer cells (Foulds, 1954; Nowell, 1976).  
 There are more than 100 distinct types of cancer, and subtypes of tumors can 
be found within specific organs. My thesis focused on the molecular genetics of 
human leukemia. 
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2. Leukemia 
 
 Leukemia is defined as a cancer of the hematopoietic system and is 
characterized by an abnormal proliferation of white blood cells. Leukemia 
significantly contributes to the overall cancer burden: worldwide, over 200’000 
people are confronted with the disease every year and for more than 80%, the 
disease ends tragically (WHO, 2002). 
 Leukemia can clinically and biologically be divided in acute and chronic forms: 
Acute leukemia is characterized by the rapid accumulation of immature blood cells, 
resulting from a differentiation block. This crowding makes the bone marrow unable 
to produce healthy blood cells. Acute forms of leukemia peak in childhood and 
elderly people. Chronic leukemia is distinguished by excessive build up of more 
mature and differentiated, but still abnormal, blood cells. Typically taking months to 
years to progress, the cells are produced at a much higher rate than normal cells, 
resulting in a large number of abnormal white blood cells in the blood. Chronic 
leukemia mostly occurs in older people, but can theoretically occur in any age group. 
Biologically, leukemias are classified into lymphocytic or myeloid, dependent on 
which cell population of the blood-forming system is affected and based on the 
molecular genetic lesions. 
 
 
 
3. Molecular genetics of leukemia 
 
 There is abundant evidence that most hematological malignacies includes 
clonal disorders characterized by acquired somatic genetic alterations in 
hematopoietic progenitors. 
 Non-random chromosome aberrations (inversions, reciprocal translocations, 
insertions, deletions, trisomies and monosomies) are found at diagnosis in leukemic 
blasts of approximately 55% of adults with acute myeloid leukemia (AML) and the 
pre-treatment karyotype has long been recognized as the most important 
independent predictor of clinical outcome in this disease. As a consequence, 
chromosome-banding analysis has become a part of routine diagnostics and several 
cytogenetic abnormalities are considered in the recent WHO classification of AML. 
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 However, approximately 45% of AML patients lack any major chromosomal 
abnormalities and the identification of pathogenetically relevant genetic lesions as 
well as the discrimination between prognostically different subsets of patients within 
this group remains a major challenge (Frohling, 2005). New methods like 
comparative genomic hybridization (CGH) arrays or genome wide sequencing will 
identify genome-wide disease-related genetic aberrations that have not yet been 
detected by existing technologies (Inazawa, 2004; Mullighan, 2007; Ley, 2008). 
 Clinical and experimental research suggests that the molecular pathogenesis 
of acute leukemia falls into two broadly defined functional complementation groups. 
One group, often referred as class I mutations, comprises mutations that activate 
distinct signal transduction pathways that enhance cellular proliferation and/or 
survival of hematopoietic progenitors. Another group, class II mutations, comprises 
mutations that affect transcription factors or components of the transcriptional co-
activation complex resulting in impaired hematopoietic differentiation and/or aberrant 
acquisition of self-renewal properties by hematopoietic progenitors at a particular 
step of differentiation (Frohling, 2005; Kelly, 2002) (Figure 1). In general, mutations 
conferring proliferative and/or survival advantage to hematopoietic progenitors are 
consequences of aberrant activation of signal transduction pathway components 
such as protein tyrosine kinases (PTK) (JAK2, FLT3, KIT, ABL1, PDGFR). By itself, 
over-expression of several activated PTKs has been shown to be sufficient to 
transform cells in vitro and to induce myelo- and/or lymphoproliferative disorders 
mimicking chronic leukemia in animal models ranging from zebrafish to mice.  
 Mutations impairing differentiation of hematopoietic cells are targeting 
transcriptional regulators essential for normal hematopoietic development, like CBF, 
RARα or MLL. Although they have oncogenic potential, these mutations are 
generally not sufficient to induce a malignant phenotype in vivo. Several mutations 
within each of these groups rarely occur in the same AML patient whereas mutations 
between complementation groups often occur together in the same AML, indicating 
functional cooperation between these two groups, and thus the multi-step 
pathogenesis in the induction of the leukemic phenotype (Frohling, 2005; Gilliland, 
2004). Cooperativity between different mutations has been validated in several 
mouse leukemia models (Grisolano, 2003; Kelly, 2002).  
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Figure 1: A two-hit model for acute leukemia.  
In leukemias, two types of genetic alterations are distinguished and referred to as class I 
and class II mutations. Class I mutations provide proliferative and/or survival advantage and 
are sufficient to induce a myeloproliferative disease (MPD) in mouse models. Class II 
mutations impair differentiation and result in a myelodysplastic syndrome-like disease (MDS) 
in mouse models. Cooperation of class I mutations with class II mutations is necessary to 
induce a leukemia phenotype. 
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 3.1 Class I mutations 
 Class I mutations include different protein tyrosine kinases that become 
constitutively activated by either fusion to a N-terminal partner protein (often 
providing an oligomerization domain) or by distinct point mutations in the kinase 
domain or internal tandem repeats in the juxtamembrane domain (Chalandon, 2005; 
Steffen, 2005). Two important examples are further mentioned here: 
 FLT3. The FMS-like PTK 3 (FLT3) gene, encoding a transmembrane class III 
receptor PTK, plays a crucial role in normal hematopoiesis. In normal bone marrow, 
FLT3 is expressed at high levels in early progenitor cells but is also expressed at 
abundant levels in a high proportion of cases of acute leukemia, suggesting a role in 
survival or proliferation of leukemic blasts. Over a decade ago, the FLT3 internal 
tandem duplication (ITD) in the juxtamembrane domain were discovered and more 
than 20% of adult and 10% of pediatric AML patients harbour this mutation (Nakao, 
1996). Kinase domain FLT3 mutations have also be found to be present in leukemic 
blasts of about 7% of AML and in less than 5% of ALL patients. Both mutation types 
lead to deregulated kinase activity. In vitro studies have suggested that FLT3 
mediates its proliferative and anti-apoptotic effects through several signalling 
pathways including STAT5, RAS/MAPK and PI3K/AKT (Chalandon, 2005; Steffen, 
2005, Choudhary, 2005). Several studies have shown that expression of mutated 
FLT3 induces a lethal myelo-lymphoproliferative disease in mice (Kelly, 2002; 
Grundler, 2003). 
 ABL1. Almost half a century ago, Nowell and Hungerford described a distinct 
cytogenetic abnormality in cells from patients with chronic myeloid leukemia (CML) 
as the Philadelphia chromosome (Nowell, 1960). It took more than two decades to 
characterize the Philadelphia chromosome as the consequence of a translocation 
between chromosome 9 and 22 leading to a fusion of the BCR gene to the ABL1 
PTK gene. This translocation is found in more than 90% of patients with CML 
(Sherbenou, 2007). Although the BCR/ABL1 fusion is exceptionally rare in T-cell 
acute lymphoblastic leukemia (ALL), recent findings suggest that ABL1 fusions also 
play a role in the pathogenesis of T-ALL (Graux, 2004). A fluorescent in situ 
hybridization-based screen detected marked extra-chromosomal episomal 
amplification of ABL1 in more than 5% of the patients. Further mapping of the 
episome showed a fusion of ABL including the kinase domain to the nucleoporin 214 
(NUP214) gene. In the tumor cells this translocation is often associated with other 
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genetic lesion such as deregulated expression of the homeobox genes HOX11 
(TLX1) or HOX11L2 (TLX3) or deletion of the cell cycle inhibitor CDKN2A (Graux, 
2004). Apart from the NUP214/ABL1 fusion, variant ABL1 fusions such as ETV6-
ABL1 or EML1-ABL1 have also been reported in T-ALL with a lower incidence (De 
Keersmaecker, 2005; Van Limbergen, 2001). 
 
 
 
4. Therapeutic targeting of oncogenic PTK activity 
 
 The entire set of genes encoding for protein kinases (also referred as the 
human kinome) encompasses more than 500 members and of these, more than a 
third have been associated so far with cancer (Manning, 2002). The development of 
small molecule inhibitors targeting aberrant PTK activity represents a milestone in 
cancer research. The most prominent example is imatinib mesylate (also known as 
Gleevec, Novartis), blocking ABL, KIT and PDGFR. It has become first-line therapy 
of newly diagnosed Philadelphia-chromosome positive CML in chronic phase 
reaching hematologic and cytogenetic response rates of >80-90% (Deininger, 2005). 
However, the development of resistance to imatinib remains a major challenge to be 
overcome. Imatinib resistance of BCR/ABL-positive leukemia has been attributed to 
at least four different molecular mechanisms: emergence of point mutations in the 
BCR/ABL kinase domain, over-expression of the BCR/ABL fusion gene, 
compensatory switch to another kinase pathway, extra-cellular sequestration of 
imatinib by p-glycoprotein–mediated active drug efflux from the target cell. Second 
generation related small molecule PTK inhibitors such as Nilotinib or Dasitinib are 
able to block some but not all imatinib-resistant ABL mutations (Hantschel, 2008). 
Another important therapeutic target is FLT3 receptor tyrosine kinase. FLT3 is 
constitutively active in 30% of adult AML cases by either internal tandem 
duplications (ITDs) or kinase domain mutations. Several small-molecule FLT3 
inhibitors (such as PKC-412, CEP701, SU11248, MLN518) have been identified and 
are currently undergoing clinical trials (Knapper, 2006). Similar to ABL, acquired 
additional mutations can result in resistance against FLT3 inhibitors and prompted 
the search for novel, structurally diverse FLT3 inhibitors that could be alternatively 
used to override drug resistance (Heidel, 2006, Weisberg, 2008). 
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  The number of newly developed compounds with inhibitory activity 
against PTKs is growing fast and it is foreseeable that we will soon have at hand a 
large number of potent small molecule inhibitors that target different oncogenic 
kinases involved in various hematologic malignancies and other cancers. However, 
mutations of the targets as a consequence of adaptive resistance will always be a 
threat to this approach, and therefore the underlying molecular mechanisms need to 
be investigated to identify critical downstream signalling pathways that could be 
efficiently targeted (Pear, 2000; Chalandon, 2005). 
 
 
 
5. Therapeutic targeting of critical downstream messengers 
 
 The transforming activity of oncogenic PTKs is mediated by parallel activation 
of several downstream signalling pathways. In general, multiple constitutively auto-
phosphorylated tyrosine residues of an oncogenic PTK can serve as a docking site 
for multiple adapters or signalling mediators to become themselves activated 
through a chain of consecutive phosphorylation events. Final downstream mediators 
of this complex signalling network are mostly phospho-proteins that translocate from 
the cytoplasm to the nucleus of the cells to act as transcriptional regulators 
activating a distinct group of target genes. Signalling pathways that act as mediators 
of leukemic PTKs include PI3K/AKT, RAS/MAPK, JAK/STAT, SHH or NFκB 
(Chalandon, 2005; Steelman, 2008) (Figure 2). A major effector of leukemogenic 
PTK activity is the JAK/STAT signal transduction pathway. 
 
5.1 The JAK/STAT pathway 
 The JAK/STAT pathway is a key signalling pathway activated by ligation of a 
large number of different cytokine receptors. It consists of three families of genes: 
the JAKs, or Janus family of protein tyrosine kinases, the signal transducers and 
activators of transcription (STAT) family, encompassing seven proteins, and the 
suppressors of cytokine signalling/cytokine-induced SH2-containing (SOCS/CIS) 
family, which serves as endogenous inhibitors. The JAK/STAT pathway generally 
mediates signals from a cytokine receptor to the nucleus. 
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Figure 2: Sites of mutation that can result in activation of the Raf/MEK/ERK, 
PI3K/PTEN/Akt/mTOR and Jak/STAT pathways in hematopoietic cells.  
Mutations have been detected in FLT3, KIT, RAS and JAK. The BCR/ABL chromosomal 
translocation is present in virtually all chronic myeloid leukemias (CMLs) and some acute 
lymphocytic leukemias (ALLs). Many of these mutations and chromosomal translocations 
result in activation of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades. The 
frequently mutated genes are indicated by a jagged symbol (adapted from Steelman, 2008). 
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 JAK proteins associate with cytokine receptors, and ligand-stimulation of the 
cytokine receptor and activation of associated JAKs lead to phosphorylation of 
specific tyrosine residues on the receptor. This allows (SH2-containing) signalling 
proteins, including STATs, to bind. JAKs will then phosphorylate STATs leading to 
hetero-and homodimer formation and translocation to the nucleus, where the 
complexes can bind to specific DNA response elements and activate gene 
transcription (Kisseleva, 2002) (Figure 3). The JAK/STAT pathway is negatively 
regulated mainly by the SOCS and CIS families of proteins or alternatively by 
protein-tyrosine phosphatases (such as PTP and SHP2) as well as by 
ubiquitinylation and degradation (Steelman, 2008). 
 Constitutive activation of the JAK/STAT pathway occurs in a broad spectrum 
of human cancers, including solid tumors and hematological malignancies. 
Constitutive PTK activity, resulting from fusion proteins or point mutations, is a 
hallmark of many hematological malignancies such as myeloproliferative diseases 
(MPD), AML, ALL and CML. These constitutive active PTKs abrogate the cytokine 
dependence of certain hematopoietic cell lines and are not dependent on ligand 
binding (Levine, 2007; Stirewalt, 2003).  
Constitutive STAT activation has been found in many human cancers. 
Constitutive STAT activation has been generally linked to transformation by specific 
mutated constitutive active PTKs, such as BCR/ABL, TEL/PDGFRβ, TEL/JAK2 or 
FLT3 mutations. Of these fusion proteins, BCR/ABL interacts with STAT5 and can 
activate STAT5 independently of JAK2, suggesting that STAT5 may be directly 
phosphorylated and activated by the fusion protein. Activation of STAT5 has been 
found to be essential for efficient transformation of hematopoietic cells by BCR/ABL 
or TEL/JAK2 (Steelman, 2008; Schwaller, 2000). STAT5, with its two isoforms, 
STAT5a and STAT5b, is an important regulator of proliferation of hematopoietic cells 
in response to cytokines, growth factors and growth hormones (Mui, 1995). In 
hematopoietic cells, STAT5 regulates the expression of several PTK-inducible genes 
such as Bcl-XL or A1, Oncostatin M (OSM), cyclin D1 or PIM1 (Socolovsky, 1999; 
Yoshimura, 1996; Matsumura, 1999; Lilly, 1992). 
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Figure 3: Mechanisms of activation of JAK2 kinase activity by mutations in the FLT3 
signalling pathway. 
A. FLT3 ligand binds the FLT3 receptor, which results in JAK2 phosphorylation, recruitment 
of STAT signalling proteins, phosphorylation and activation of downstream signalling 
pathways including STAT transcription factors, MAPK signalling proteins and the PI3K-AKT 
pathway. Negative regulation of JAK2 is mediated by SOCS proteins 
B. The oncogenic FLT3 receptor harbouring an internal tandem duplication (ITD) mutation in 
the juxtamemebrane domain undergoes ligand-independent activation, which also results in 
JAK2 phosphorylation, recruitment of STAT proteins and activation of downstream signalling 
pathways. 
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 6. The PIM family of serine/threonine kinases 
 
 Cloning of retroviral murine leukemia virus (MLV) integration sites in c-myc-
induced malignant murine lymphomas led to the identification of the PIM (Proviral 
Integration Moloney leukemia virus) genes (Cuypers, 1984). There are three 
different PIM genes, located on chromosomes 6, X and 22, encoding three 
serine/threonine kinases: PIM1, PIM2 and PIM3. At the amino acid level, PIM2 and 
PIM3 show 61% and 71% identity to PIM1, respectively (van der Lugt, 1995; Baytel, 
1998; Allen, 1996). PIM1 and PIM2 genes are characterized by alternative 
transcriptional start sites that allow the expression of several isoforms, all containing 
the entire kinase domain. PIM1 and PIM2 are ubiquitously expressed at low levels in 
many tissues and are strongly induced in leukocytes in response to a large number 
of cytokines including IL2, IL3, IL4, IL5, IL6, IL7, IL9, IL12, IL15, GM-CSF, G-CSF, 
interferon α, interferon γ, EPO, TPO, prolactin, concanavalin A, lipopolysaccharide or 
phorbol myristate acetate (Allen, 1997; Dautry, 1988; Lilly, 1992; Temple, 2001; 
Domen, 1993; Matikainen, 1999; Yip-Schneider, 1995; Miura, 1994; Borg, 1999; 
Wingett, 1996; Bachmann, 2005, Wang, 2001). In normal animals, highest PIM1 
mRNA levels were found in thymus and testis, whereas highest PIM2 mRNA levels 
were seen in the brain and thymus and PIM3 mRNA is most abundant in the kidney, 
breast and brain (Selten, 1985; Allen, 1997; Feldman, 1998). PIM kinases seem to 
be constitutive active molecules with a short half-life (of minutes) and their regulation 
appear to be largely at the level of transcription and degradation by the proteosome 
(Mikkers, 2002; Fox, 2003). There seem to be a certain degree of functional 
redundancy among the PIM kinase family: retroviral infection of myc-induced 
lymphomas in PIM1-/- mice resulted in tagging and up-regulation of PIM2 and 
infection of lymphomas lacking both PIM1 and PIM2 resulted in tagging PIM3 
(Mikkers, 2002; Bachmann, 2005). Mice lacking PIM1 or PIM2 are viable and fertile 
with only mild defects in the hematopoietic system. Surviving mice lacking all three 
PIM kinases display reduced body size owing to decreased cell number in virtually 
all tissues but have a normal lifespan (Mikkers, 2004). Colony forming assays with 
bone marrow from PIM1-/- PIM2-/- PIM3-/- mice demonstrated that PIMs act 
redundantly in clonogenic growth in response to IL3, IL6, SCF and TPO; however, 
PIM1 seems to be the most crucial PIM for these responses (Mikkers, 2004). As PIM 
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kinases contribute to both cell proliferation and survival, they could provide a 
selective advantage in tumorigenesis. 
 The best-studied PIM kinase is PIM1. Examination of the substrate sequence 
specificity of PIM1 revealed strong preference for the peptide K-R-R-A-S/T-G-P with 
the presence of basic amino acid residues at the N terminal side being essential for 
substrate recognition. This suggests that under in vitro conditions, (K/R)3-X-S/T-X (X 
being neither basic nor large hydrophobic residue) might be the optimized PIM1 
recognition site (Friedmann, 1992). Stepwise replacement experiments allowed 
further refinement of the consensus sequence for PIM1 phosphorylation to K/R-K/R-
K-R/K-L-S/T-X where X is an amino acid residue with a small side chain (Palaty, 
1997). In addition to phosphorylation of cellular substrates, these in vitro 
experiments also revealed auto-phosphorylating activity of PIM1 (Hoover, 1991; 
Padma, 1991). Mass-spectrometric analysis of GST-fusions of Xenopus laevi PIM1 
identified potential auto-phosphorylation sites including S190 and T205, both 
conserved between species (Palaty, 1997). Negative regulation of the stability of 
PIM1 by the protein phosphatase 2A (PP2A) suggests that auto-phosphorylation 
and/or phosphorylation by so far unknown regulatory kinases are important 
determinants of PIM1 function (Losman, 2003; Ma, 2007). PIM1 has been implicated 
in signal transduction and transcriptional regulation, as well as cell cycle regulation 
and cell survival (Bachmann, 2005; Wang, 2001). The effect of PIM1 in signal 
transduction seems to be mediated by several substrates such as SOCS1 and 
SOCS3, that are involved in negative regulation of cytokine-induced JAK/STAT 
signaling (Chen, 2002), or the nuclear adapter protein p100 (a PIM1 binding 
partner), that is an activation factor of transcription factor c-Myb (Leverson, 1998). 
Other potential PIM1 substrates suggest that PIM1 can regulate nuclear 
transcription. Indeed, HP1 (heterochromatin-associated protein 1) and PAP1 (PIM1 
associated protein) function in transcriptional repression by the silencing of 
chromatin and regulation of mRNA splicing, respectively (Koike, 2000; Maita, 2000). 
PIM1-mediated cell cycle regulation is driven by active phosphorylation, which 
enhances the activity of cell cycle promoters like Cdc25A (a G1 regulator) and 
Cdc25C (a G2/M regulator) as well as the inactivation of cell cycle inhibitors such as 
p21Cip1/Waf1 and C-TAK1. PIM1 also binds and directly phosphorylates p27/KIP1 
(CDKN1B) at residues T157 and T198 that allow binding of p27/KIP1 to 14-3-3 
proteins resulting in its nuclear export and proteosome-dependent degradation 
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 (Mochizuki, 1999, Bachmann, 2004; Wang, 2002, Liu 2008). Moreover, 
Zippo et al. showed that PIM1 acts a a cofactor of myc, phosphorylating chromatine 
at myc-target loci and contributes to a myc-dependent transformation (Zippo, 2007). 
 Further associations of PIM1 with the nuclear mitotic apparatus protein 
complexes seem to facilitate the progression through mitosis (Bhattacharya, 2002). 
As a whole, deregulated PIM1 activity would result in acceleration of the passage of 
cells from G2 into M-phase of the cycle. The role of PIM1 in apoptosis and survival is 
exercised by direct linking with proteins of the Bcl2 family: PIM1 phosphorylates and 
inhibits the pro-apoptotic protein BAD (Aho, 2004; Kim, 2006; Macdonald, 2006) 
(Figure 4). Taken together, deregulated constitutive active PIM kinases enhancing 
cellular proliferation and survival could play a role in oncogenesis. 
 
 
 
 
 
Figure 4: PIM kinases.  
PIM kinases are downstream targets of oncogenic protein tyrosine kinases (PTKs) such as 
BCR/ABL or FLT3/ITD and mutated transcription factors (TFs) like MLL-X fusions. 
Phosphorylation of various targets supports cellular growth and survival. 
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6.1 Role of PIM kinases in cancer 
 Identification of PIM1 as being deregulated through recurrent proviral 
integration sites in murine lymphomas suggested early on that it might play a role in 
cancer pathogenesis (Cuypers, 1984; Mikkers, 2002). The tumorigenic activity of 
PIM1 and PIM2 kinases as cooperating oncogenes has been demonstrated in 
various transgenic mouse models. Early studies found PIM1 being over-expressed 
in 30% of human myeloid and lymphoid leukemias in absence of any PIM1 gene 
rearrangements or amplifications (Amson, 1989; Selten, 1986). In several cellular 
models of malignant myeloproliferative disorders, PIM1 expression was found to be 
up-regulated and proposed to be a mediator of cell proliferation and survival of 
oncogenic protein tyrosine kinases such as BCR/ABL or FLT3-ITD (Nieborowska-
Skorska, 2002; Kim, 2005; Liang, 1996; Adam, 2006). Elevated levels of PIM1 found 
in a large fraction of human AML are most probably the consequence of the 
presence of activated FLT3 mutations in conjunction with class II mutation-mediated 
aberrant activation of transcriptional regulators of PIM1 (Hu, 2007). PIM1 over-
expression alone is sufficient to induce cytokine independence in murine 
hematopoietic cells (Nosaka, 2002; Pogacic, 2007). Apart from leukemia, PIM1 
seem to play an important role in the biology of malignant B cell lymphomas and 
prostate cancer. 
 In diffuse large B-cell lymphomas (DLBCL) and less frequently in other B-cell 
malignancies, PIM1 is targeted by aberrant somatic hypermutation (ASHM). ASHM-
mediated PIM1 mutations have been detected in up to 50% of DLBCL cases, mostly 
affecting the coding sequence or the 5’ untranslated region of PIM1 (Pasqualucci, 
2001). Although those mutations involving the coding exons are predictive of change 
in the structure and in some cases, the function of the PIM1 protein, their role for the 
pathogenesis of B-cell lymphomas remained unclear. These lymphomas are 
characterized by chromosomal translocations leading to deregulation of several 
proto-oncogenes controlled by the immunoglobulin gene promotor and enhancer 
elements. It has been demonstrated that BCL6 translocations involve 
immunogloblulin (Ig) genes but also a number of non-Ig loci as partners including 
PIM1 in some rare cases (Akasaka, 2000). 
 Several studies have proposed that PIM1 over-expression can be used as a 
biomarker to distinguish between benign lesions and malignant glands in prostate 
cancer samples (Dhanasekaran, 2001). Gene expression profiling in human and 
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 mouse prostate cancer tissues found co-transcriptional regulation of PIM1 
and c-myc, possibly mediating a synergistic oncogenic effect in prostate cancer 
(Dhanasekaran, 2001; Ellwood-Yen, 2003; Zippo, 2007). Generally, decreased or 
absent PIM1 expression significantly correlated with measures of poor outcome. In 
vitro studies found that PIM1 induced genetic instability in human prostate epithelial 
cells as cells over-expressing PIM1 showed abnormal mitotic spindles, centrosome 
amplification and chromosome mis-aggregations (Valdman, 2004). 
 However, PIM1 is not the only PIM kinase involved in B cell lymphomas, solid 
cancers and leukemia. PIM2 was reported being over-expressed and associated 
with several malignancies originating from the B-cell lineage, including CLL and 
DLBCL as well as in prostate cancer (Yoshida, 1999; Cohen, 2004; Dai, 2005). In 
contrast, PIM3 has so far only been found in solid cancer but not in leukemia (Fujii, 
2005; Li, 2006).  
 Taken together, increased expression of one or several PIM kinases are 
found in human hematological malignancies as well as solid cancers. By using 
siRNA-mediated strategies, PIM knockdown significantly impaired growth and/or 
survival of leukemia, prostate and liver cancer cells (Li, 2006; Fujii, 2005; Dai, 2005; 
Adam, 2006). Interestingly, whereas certain tumor cells (e.g. prostate and liver cell 
lines) were severely affected by knockdown of a single PIM kinase, others (some but 
not all leukemia cell lines) needed more than the knockdown of one single PIM to be 
significantly affected. These studies all suggest that inhibition of aberrant PIM 
activity by small molecules could open a new avenue for cancer therapy. 
 
6.2 Small molecule inhibitors of PIM kinases 
 As outlined above, there is increasing evidence that PIM1 might be an 
important downstream player in cancer development and progression. The nature of 
PIM1 as constitutive active serine/threonine kinase and its deregulated expression in 
various cancers have made it a promising new drug target. An increasing number of 
ATP-competitive small molecule inhibitors of protein kinases have been successfully 
developed as new therapeutic option for cancer. However, owing to the similarity of 
the ATP binding sites between kinases, it has been challenging to identify specific 
inhibitors. PIM1 is unique among protein kinases due to the absence of the 
canonical hydrogen bond donor in the hinge region (the region deep in the ATP 
binding pocket linking the upper and lower lobe) that is a key element for the binding 
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of many ATP-mimetic kinase inhibitors. Due to this structural peculiarity, classical 
ATP-competitive kinase inhibitors may only weakly bind to the PIM family of kinases 
(Kumar, 2005). The earliest reported inhibitor of PIM1 function is LY294002, which 
was initially identified as a specific PI3K inhibitor (Jacobs, 2005). Seventy co-crystal 
structures of low molecular mass, low-affinity compounds with PIM1 have been 
solved in order to identify novel chemical classes as potential PIM1 inhibitors 
(Kumar, 2005). Recently, Ruboxistaurin, a PKCβ inhibitor being previously used in 
trials to treat diabetic complications, has been found to efficiently inhibit PIM1 and in 
vivo experiments suggest its potential use in acute myeloid leukemia with FLT3 
mutations (Fedorov, 2007). Quercetagetin has also been reported to be a 
moderately potent and selective cell permeable inhibitor of PIM1 kinase that is able 
to inhibit PIM1 activity in prostate cancer cells in a dose-dependent manner (Holder, 
2007). A series of substituted pyridone molecules was recently identified from a high 
throughput screen as potent inhibitors of PIM1 kinase; they may serve as useful 
starting scaffolds for the development of other improved and selective PIM1 
inhibitors (Cheney, 2007; Tong, 2008). 
 During my PhD, I have investigated the role of PIM kinases in the 
pathogenesis of hematological malignancies induced by oncogenic PTKs and I have 
tested several types of potential small molecule inhibitors targeting PIM kinases. 
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 II. Role of PIM kinases in the pathogenesis of FLT3-
ITD induced myeloproliferations 
 
 
1. Results 
 
 Increasing clinical and experimental evidence suggested that aberrant 
expression of PIM kinases might play an important role in the pathogenesis of 
leukemic disorders that are induced by constitutive activation of PTKs such as ABL, 
JAK2 or FLT3. Multiple studies have reported PIM1 and/or PIM2 being up-regulated 
in hematological malignancies harbouring mutated activated PTKs (Adam, 2006; 
Kim, 2005; Amson, 1989; Nieborowska-Skorska, 2002). Deregulated PIM kinase 
activity seem to be important for maintenance of a transformed hematopoietic cell as 
functional interference by expression of dominant-negative acting PIM mutants or 
PIM-isoforme specific siRNA significantly impaired growth and proliferation of human 
and mouse hematopoietic cells that where transformed by BCR/ABL or FLT3-ITD 
(Adam, 2006). Over-expression of PIM1 is able to transform growth-factor-
dependent hematopoietic cells and to induce a lethal leukemia-like disease in mice 
after a long latency (Nosaka, 2002; Grundler, unpublished observation). However, it 
is not known whether PIM kinases are essential for the induction of PTK-mediated 
leukemic disorders.  
 Expression of FLT3-ITD induces MPD in transgenic mice, as well as in bone 
marrow transplantation models (Kelly, 2002; Gilliland, 2003, Grundler, 2005). By 
using a genetic approach, we investigated the role of PIM kinases for the 
development of malignant myeloproliferation mediated by FLT3-ITD. 
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1.1 In vitro and in vivo leukemogenic activity of FLT3-ITD is independent of 
PIM2 
 To investigate the role of PIM kinases in hematological diseases induced by 
oncogenic protein tyrosine kinases, we expressed the constitutively active FLT3-ITD 
mutant in primary murine bone marrow cells. Retroviral expression of FLT3-ITD in 
wild type bone marrow cells induced growth factor-independent growth as shown in 
colony forming assays as well as in liquid culture (Figure 5A). Expression of FLT3-
ITD in PIM1-/- bone marrow cells resulted in a significant lower number of colonies 
growing with and without IL3. No differences in colony formation and growth 
properties were observed in WT (FVB/N) and PIM2-/- bone marrow cells expressing 
FLT3-ITD when grown in presence or absence of IL3 (Figure 5B). Liquid culture of 
the cells over five days revealed no difference in viability but a general reduced 
growth rate of bone marrow cells originating from PIM1-/- animals compared to PIM2-
/- or wild type mice (Figure 5C). These in vitro results suggest that PIM1 and not 
PIM2 is involved in signalling events that are essential for IL3 and/or FLT3-ITD 
regulated proliferation. 
 To study the role of PIMs in FLT3-ITD mediated leukemogenesis in vivo, we 
performed bone marrow transplantations with cells from WT, PIM1-/- or PIM2-/- donor 
mice. Cells were infected with MSCV-FLT3-ITD-EGFP or control EGFP retrovirus 
and transplanted into sub-lethally (750rad) irradiated synergic (FVB/N) recipient 
mice. Mice that were transplanted with cells lacking PIM1 developed no 
hematological disorder during one year of post-transplant observation (Figure 6A). 
Histological analysis of the normal sized spleens of FLT3-ITD-transplanted animals 
revealed no pathological changes six months after transplantation (Figure 6C). In 
contrast, animals that received a transplant of FLT3-ITD-tranduced bone marrow 
cells from WT or PIM2-/- mice developed a myeloproliferative disorder characterized 
by a massive expansion of EGFP-positive myeloid (CD11b+) cells in the peripheral 
blood characterized by FACS analysis 26 days post transplantation (not shown). 
There was no significant difference in survival between recipients of WT versus 
PIM2-/- bone marrow transduced with FLT3-ITD. Both mice groups succumbed to 
disease with a median survival time of 108 and 138 days, respectively (Figure 6A). 
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Figure 5: In vitro and in vivo FLT3-ITD mediated transformation in presence and 
absence of PIM serine/threonine kinases. 
A. Schematic representation of the experimental settings. 
B. Comparative analysis of clonogenic growth of FLT3-ITD expressing bone marrow cells 
from wildtype and PIM1-/-, or PIM2-/- mice: 104 EGFP+ cells were sorted 48h after infection 
and plated in methylcellulose in presence of absence of IL3.  
C. Comparative analysis of liquid culture growth of FLT3-ITD expressing bone marrow cells 
from wildtype and PIM1-/-, or PIM2-/- mice: 1-5.105 cells were plated 48h after infection in 
presence or absence of IL3 and counted each day in triplicates. 
  20 
 Macroscopically, diseased mice of both groups showed enlarged spleens and 
thymi. Histopathological examinations of the spleens revealed extensive infiltrations 
with neoplastic myeloid cells (Figure 6C). All mice receiving a transplant of FLT3-
ITD transduced bone marrow developed exactly the same mixed myeloid/T-
lymphoid phenotype, as published before (Grundler, 2005). Following the EGFP+ 
reconstituted cells by flow cytometry revealed significant expansion of FLT3-ITD 
expressing WT or PIM2-/- cells within the first month post transplantation. In contrast, 
although detectable over several weeks, FLT3-ITD expressing PIM1-/- cells 
underwent no significant expansion (Figure 6B).  
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 Figure 6: Transplantation of wildtype (WT) or PIM2-/-, but not PIM1-/- leads to 
FLT3-ITD induced myeloproliferative disorder. 
A. Kaplan Meier survival plot: WT, PIM1-/- or PIM2-/- bone marrow was transduced with 
FLT3-ITD or empty vector (MigRI) as indicated and transplanted into sub-lethally irradiated 
(750rad) recipient mice. All mice that underwent transplantation with FLT3-ITD transduced 
WT or PIM2-/- bone marrow died, or were sacrificed because of disease conditions 
B. Flow cytometric analysis of EGFP+ cells in peripheral blood samples post transplant. 
C. Histopathological analysis of spleen biopsies from animals transplanted with FLT3-ITD 
expressing bone marrow cells. Extensive splenic myeloid infiltrations in animals that 
received wild-type or PIM2-7- FLT3-ITD+ cells were shown (rp= red pulp, wp= white pulp, 
infiltr= infiltration). 
 
 
 
 Although the experiments were performed in the same way for all conditions, 
we could not exclude that the absence of FLT3-ITD-mediated disease could result 
from the inability of PIM1-/- cells to reconstitute irradiated mice. During the first series 
of experiments, a non-lethal irradiation dose was applied to the recipient mice 
(750rad). To further exclude the possibility of a homing failure in PIM1-/- cells, we 
increased the irradiation to a lethal dose of 900rad and repeated the experiments. 
Again, animals receiving FLT3-ITD expressing cells from WT and PIM2-/- donors did 
develop an identical MPD phenotype as described above. In contrast, all recipients 
transplanted with PIM1-/- bone marrow expressing either the control vector or MSCV-
FLT3-ITD-EGFP died within three weeks most probably from a lack of bone marrow 
reconstitution (Figure 7A). A rapid decline of all hematopoietic cell lineages was 
observed in the first two weeks after transplantation (Figure 7B). To exclude the 
possibility of a quantitative difference in transplanted hematopoietic stem cells, we 
compared the number of lin-, Sca1+ and c-kit+ cells but no difference was found 
(Figure 7C). Taken together, these unexpected results suggested that PIM1 could 
play an essential role in early bone marrow reconstitution. 
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Figure 7: PIM1-/- bone marrow cells do not reconstitute lethally irradiated recipient 
animals. 
A. Overall survival of lethally irradiated (950rad) recipients receiving WT, PIM1-/- or PIM2-/- 
bone marrow cells. 
B. Hematopoietic reconstitution following transplantation of 3.106 WT (n=4), PIM1-/- (n=5) or 
PIM2-/- (n=5) bone marrow cells into lethally irradiated mice. Data represent mean ± SD. 
(WBC= peripheral blood leukocyte count, RBC= peripheral blood erythrocyte count, PTK= 
peripheral blood platelet count). 
C. Analysis of Lin- Sca1+ c-kit+ cells in the bone marrow of 6-8 weeks old WT, PIM1-/- and 
PIM2-/- female mice. 
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 1.2 Role of PIM1 in early homing and migration of HSCs 
 The observed lack of early bone marrow reconstitution could be theoretically 
based on a defect of hematopoietic stem cell homing and migration towards their 
niches or on insufficient expansion due to limited self-renewal. Previous studies 
suggested that engraftment of HSCs could be divided into three phases: homing, 
trans-marrow migration and lodgement in the niche (Nilsson, 2006). The rapid 
decline (<2 weeks) of all hematopoietic lineages shortly after transplantation 
suggests that PIM1-/- hematopoietic stem cells are impaired in their homing and/or 
migration capacities. 
 In order to understand the role PIM1 plays in homing, we labelled bone 
marrow from WT and PIM1-/- mice with the vital dye CFSE (Carboxyfluorescein 
succinimidyl ester) and injected equal numbers of viable, positively labelled cells 
into lethally irradiated recipients and determined the amount of cells that homed to 
the bone marrow and to the spleen 4 and 20 hours post-transplant (Figure 8A & B). 
A significant time-independent decrease in CFSE-labelled cells was observed in the 
spleen and the bone marrow of mice injected with PIM1-/- cells compared to mice 
receiving labelled cells from WT animals. No significant difference in viability of 
CFSE-labelled cells was observed between the genotypes, as determined by PI 
staining (Figure 8C). As PIM1-/- cells were not able to home to hematopoietic organs 
such as the bone marrow or the spleen, this finding suggested that PIM1 could play 
an important role in homing of hematopoietic stem cells. 
 
 
 
 
 
Figure 8: PIM1-/- bone marrow cells do not reconstitute lethally irradiated recipient 
animals and have an impaired homing capacity. 
A. Schematic representation of the experimental settings. 
B. Homing of CFSE-labelled bone marrow cells from PIM1-/- and wild-type FVB/NJ mice to 
the bone marrow (upper panel) and the spleen (lower panel) of wild-type recipients. Data 
represent the mean ± SD of duplicates. 
C. Viability of bone marrow cells from PIM1-/- and wild-type FVB/NJ mice 4 and 20 hours 
post CFSE stain was detected by PI staining. Data represent the mean ± SD of duplicates. 
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 1.3 PIM1 is a functional regulator of the CXCR4 chemokine receptor 
 Previous studies have shown that interaction of the chemokine receptor 
CXCR4 with its ligand CXCL12/SDF1α is essential for homing and trans-marrow 
migration of HSCs (Lapidot, 2005; Burger, 2006). In order to find out whether 
CXCR4 signalling could be involved in the grafting defect of PIM1-/- bone marrow, we 
first compared in vitro migration of PIM1-/- and WT bone marrow cells towards a 
CXCL12 gradient. Cells lacking PIM1 showed impaired migration, even in the 
presence of hematopoietic growth factors like IL3, IL6 and SCF (Figure 9A). Flow 
cytometric analysis of the same cells revealed that PIM1-/- cells expressed lower 
levels of surface CXCR4, but not of other surface molecules also involved in homing 
like integrins α4 and α5 (Figure 9B & D). Cellular response to CXCL12 is 
characterized by a rapid Ca2+ flux. Interestingly, almost no Ca2+ flux was observed in 
bone marrow cells lacking PIM1 when compared to wild type cells (Figure 9C). 
Furthermore, CXCL12 induced activation of CXCR4 downstream signals such as 
phosphorylation of AKT and ERK was impaired in PIM1-/- cells (not shown). These 
observations suggested that PIM1 might be a functional regulator of the 
CXCL12/CXCR4 signalling axis.  
 
 
Figure 9: Decreased steady-state CXCR4 surface expression of PIM1-/- bone marrow 
cells is associated with impaired migration and CXCL12-induced signalling. 
A. Bone marrow cells from PIM1-/- and FVB/NJ mice were allowed to migrate toward a 
CXCL12 gradient (300ng/mL) along with background migration as indicated. The migration 
index was calculated as a percentage of input cells. Data represent the mean ± SD of 
triplicates. 
B. Cell surface expression of CXCR4 on bone marrow cells from PIM1-/- and wild-type mice 
was analyzed by staining with PE-conjugated anti-mouse CD184 antibody (open 
histogram). Non-specific binding was assessed by using a PE-conjugated rat-IgG2b 
antibody (grey histogram). 
C. Calcium flux was monitored in freshly isolated WT and PIM1-/- bone marrow cells after 
stimulation with CXCL12 (300ng/mL). 
D. Cell surface expression of integrin α4 (CD49d) and integrin α5 (CD49e) was analyzed by 
staining with PE-conjugated anti-mouse CD49d and CD49e antibodies, respectively (open 
histograms). Non-specific binding was assessed with a PE-conjugated rat IgG2b and IgG2a 
antibody, respectively (grey histograms). 
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  To further investigate this possibility, endogenous PIM expression was 
down-regulated by virally expressed PIM-specific siRNA in BaF/3 cells. Knockdown 
of PIM1 resulted in a significant decrease of CXCR4 surface expression whereas 
PIM2 siRNA showed no effect (Figure 10A). Interestingly, Western Blot analysis 
revealed no change in total CXCR4 protein expression suggesting that PIM1 
selectively regulates surface CXCR4 expression (Figure 10B).  
 Likewise, expression of a dominant-negative acting PIM1 mutant (PIM1-KD, 
kinase-dead) also down-regulated surface CXCR4 level suggesting that PIM1 kinase 
activity is indeed required (Figure 10C). Taken together, these results suggested 
that PIM1 could selectively control the surface presentation of CXCR4. We therefore 
tested whether re-expression of PIM1 in PIM1-/- bone marrow cells could rescue 
surface CXCR4 expression and migration towards a CXCL12 gradient. For this, 
PIM1-/- bone marrow cells were retrovirally infected with PIM1 and CXCR4 surface 
expression was analyzed. Infected cells showed CXCR4 surface levels comparable 
with wild type cells (Figure 11A). In addition, expression of PIM1 restored the 
capability of the cells to efficiently migrate towards CXCL12 (Figure 11B). It has to 
be noted that prolonged in vitro culture of bone marrow cells (that is necessary for 
viral transduction) also affects cellular migration and might be responsible for 
increased migration observed in cells transduced with the control vector. Taken 
together, our results suggested that PIM1 is a critical regulator of CXCR4 surface 
expression and function in hematopoietic cells. 
 To further test the hypothesis that PIM1 kinase activity is required for the 
regulation of CXCR4 surface expression, I used a small molecule inhibitor against 
PIM1 (K00486) that we recently characterized (see part III). As the efficacy of this 
compound is limited to human PIM1, we treated human JURKAT T-cell leukemia 
cells, expressing high levels of PIM1 and surface CXCR4, for 2h with 10µM K00486. 
A transient but significant decrease of surface CXCR4 was observed by flow 
cytometry as well as significantly reduced migration of the cells towards a CXCL12 
gradient without affecting the viability (Figure 11C & D). These data further support 
a functional link between PIM1 kinase activity and surface expression and function 
of CXCR4. 
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Figure 10: PIM1 activity regulates CXCR4 surface expression in hematopoietic cells. 
A. Down-regulation of PIM1 but not PIM2 resulted in reduced surface expression of CXCR4 
in BaF/3 cells. BaF/3 cells were retrovirally transduced with pLMP, pLMP-siPIM1 or pLMP-
siPIM2, expressing siRNAs. Cell surface expression of CXCR4 was analyzed by staining 
with PE-conjugated anti-mouse CD184 antibody (open histogram). The level of non-specific 
binding was assessed by using a PE-conjugated rat-IgG2b as isotype control (grey 
histogram). 
B. Down-regulation of PIM1 and PIM2 protein expression was confirmed by Western Blot 
analysis. No change in total CXCR4 expression was observed. 
C Wildtype bone marrow cells were transduced with MSCV-PIM1-KD-IRES/GFP and 48h 
later surface CXCR4 was compared on EGFP+ vs. EGFP- cells. Cell surface expression of 
CXCR4 was analyzed by staining with PE conjugated anti-mouse CD184 antibody (open 
histogram). Non-specific binding was assessed as described above. 
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Figure 11: PIM1 activity regulates CXCR4 surface expression in hematopoietic cells. 
A. WT and PIM1-/- bone marrow was transduced with pMSCV mPIM1-YFP or empty vector 
(MYFP) as indicated. Cell surface expression of CXCR4 was analyzed by staining with PE-
conjugated anti-mouse CD184 antibody. 
B. Bone marrow cells from wild-type and PIM1-/- mice, transduced with pMSCV mPIM1-YFP 
or empty vector (MYFP) as indicated, were allowed to migrate toward a CXCL12 gradient 
(300ng/mL). The migration index was calculated as a percentage of input cells. Data 
represent the mean ± SD of triplicates. 
C. Treatment of human Jurkat leukemia cells with a small molecule PIM1 inhibitor (K00486, 
10µM) leads to a transient but significant reduction of surface CXCR4 expression after 2h 
(strong dotted line) and 24h (fine dotted line). Viability of the cells was not significantly 
changed within the time of the experiment determined by 7-AAD staining (not shown). 
D. Jurkat cells were allowed to migrate towards a CXCXL12 gradient (100ng/mL) with or 
without pre-treatment with the K00486 PIM1 inhibitor (2h, 10µM). Data represent the mean ± 
SD of triplicates. 
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1.4 PIM1 as mediator of elevated surface CXCR4 in human leukemic blasts 
 Several studies have previously demonstrated that elevated surface CXCR4 
expression is an adverse prognostic marker in patients with acute myeloid leukemia 
(AML) (Rombouts, 2004; Spoo, 2007). Since our results suggested that PIM1 might 
be a regulator of surface CXCR4 expression, we compared the PIM1 expression 
levels in leukemic samples that have previously been analyzed for surface CXCR4 
expression (Spoo, 2007). Interestingly, although we were limited to a small number 
of samples we observed a tendency for higher PIM1 expression in AML samples 
with high CXCR4 surface expression (p<0.05) (Figure 12A). In contrast, we found 
no significant correlation between surface CXCR4 and CXCR4 mRNA levels (Figure 
12A). These data suggested that PIM1 signalling might be necessary for increased 
CXCR4 surface expression on AML blasts.  
 In order to address this possibility we freshly isolated leukemic blasts from 
patients with newly diagnosed AML expressing high surface CXCR4. Cells were 
treated with 10µM of the PIM1 inhibitor K00486 for 30min (collaboration with C. 
Dierks and A. Spoo, Freiburg). A significant decrease in CXCR4 surface expression 
was observed in two out of 3 patient samples without impaired viability (Figure 12B). 
These observations further supported the hypothesis that PIM1 can act as an 
important regulator of surface CXCR4 expression in primary human leukemic cells.  
 As several studies have shown over-expression of PIM1 in many hematologic 
malignancies as well as solid tumors, we determined whether elevated PIM1 levels 
might also affect CXCR4 function by using Ba/F3 hematopoietic cells stably over-
expressing human PIM1 (Adam, 2006). Interestingly, transmigration towards a 
gradient of 10nM CXCL12 was significantly enhanced for PIM1 over-expressing cells 
and could be significantly impaired in the presence of the K00486 inhibitor (Figure 
12C). These results suggested that deregulated PIM1 might exert its oncogenic 
activity also through increase of CXCR4 surface expression and function. 
 
CXCR4 surface expression is regulated by ligand (CXCL12)-induced internalization 
and surface re-expression or degradation (Busillo, 2007). In order to find a 
mechanistic link between CXCR4 and PIM1, we monitored CXCR4 surface 
expression on JURKAT cells upon stimulation with CXCL12 and in presence or 
absence of the PIM1 inhibitor K00486. 
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Figure 12: Expression and regulation of PIM1 and CXCR4 in primary acute myeloid 
leukemia blasts. 
A. Expression of PIM1 and CXCR4 mRNA in leukemic cells from AML patients with high vs. 
Low surface CXCR4 expression (as described in Spoo, 2007) by Q-PCR analysis. The 
values are normalized to GAPDH levels and represent median values of two independent 
experiments performed in triplicates (one-way ANOVA: p-values ≤ 0.05). 
B. Regulation of CXCR4 surface expression in primary blasts from three AML patients upon 
treatment with the K00486 PIM1 inhibitor (30min, DMSO, 5µM or 10µM K00486). 
C. BaF/3 cells stably over-expressing human PIM1 as well as WT BaF/3 cells were allowed 
to migrate toward a CXCL12 gradient (10nM) in presence or absence of the K00486 inhibitor 
(10µM, 2h). The migration index was calculated as a percentage of input cells. 
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 After 90min of a 10nM CXCL12 exposure, most of the surface CXCR4 was 
internalized, as shown previously (Ding, 2003). Exposition of the cells for 30min to 
10nM CXCL12 followed by an extensive washing of the cells resulted in a rapid 
surface re-exposure of CXCR4 to about 80% of the starting level. Pre-treatment of 
the cells for 1h with 10µM K00486 increased the internalization of CXCR4 to more 
than 90% after 90min. Interestingly, surface re-expression after washing out K00486 
and CXCL12 was significantly impaired, reading only 40% of the starting level 
(Figure 13A). To visualize the observed effects, CXCR4 expression was analyzed 
by immunofluorescent staining at the end of the experiment (t=3.5h). CXCL12 
treatment resulted in the internalization of a significant fraction of CXCR4 and 
washing out in almost complete restoration of the CXCR4 surface level. In presence 
of the PIM1 inhibitor, CXCL12 also led to CXCR4 internalization; however after 
washing out, an important fraction of the receptor remained in the cytoplasm (Figure 
13B). To exclude unspecific effects mediated by the PIM1 inhibitor, this experiment 
was also performed with cells retrovirally expressing PIM1-specific siRNA, leading to 
significant down-regulation of PIM1 protein expression. Again, the CXCR4 surface 
re-expression after CXCL12 exposure was impaired to about 50% compared to wild 
type cells (not shown). Taken together, these experiments strongly suggested that 
PIM1 can act as regulator of CXCR4 surface expression. 
 
 
 
 
 
Figure 13: Functional inhibition of PIM1 impairs surface (re)-expression of CXCR4. 
A. Delayed ligand-induced surface (re)-expression of CXCR4 in the presence of PIM1 
inhibitor shown by flow-cytometric evaluation in Jurkat cells. 30min treatment with CXCL12 
(10nM) before washing (indicated as W) allows induction of recycling of CXCR4 on the cell 
surface evaluated 1, 2 and 3 hours after washing compared to non-washed cells. Recycling 
is delayed when cells are pre-treated for 1h with K00486 (10µM). 
B. Confocal immunofluorescence analysis of distribution of CXCR4 in Jurkat cells after 3.5 
hours treatment as mentioned in A. The left column of the panel shows CXCR4 distribution 
without PIM inhibitor, the right column of the panel with PIM1 inhibitor treatment. Propidium 
iodide was used for nuclei staining. 
 33 
  
 
 
 
 
  34 
1.5 PIM1 directly phosphorylates CXCR4 at S339 on C-terminus 
 Functional regulation of CXCR4 by PIM1 activity raised the question whether 
PIM1 kinase could directly interact and modify the CXCR4 receptor. 
Immunolocalization experiments in Jurkat cells supported this possibility, showing 
partial overlapping signals for CXCR4 and PIM1, predominantly located in the 
cytoplasm of the cells (Figure 14A). 
 Previous studies have shown that CXCR4 undergoes ligand dependent and 
independent endocytosis and surface re-expression depending on the integrity of the 
intracellular C-terminal domain, rich in serine and threonine residues (Busillo, 2007). 
We identified three putative PIM1 recognition sites in this region: S325, S330 and S 
339, each containing the preferred -5 or -3 arginine relative to the target serine 
(Figure 14B). To assess their potential as PIM1 phosphorylation sites, 46 C-terminal 
residues of CXCR4 were expressed as a GST fusion protein and treated in vitro with 
purified PIM1 protein. Only one single PIM1-dependent phosphorylation was 
detected by mass spectrometry (all mass spectrometry analysis were performed by 
Stefan Knapp and co-workers, SGC, Oxford, UK) as a shift of 80 Da in the intact 
protein mass. No phosphorylation was detected on GST alone.  
 To further define the phosphorylation site, we prepared a series of C-terminal 
deletion mutants and treated them with PIM1 and analyzed changes in 
phosphorylation by mass spectrometry. Phosphorylation was observed for short 
deletions including the C46Δ13 construct but was lost upon further truncations, 
locating the likely substrate site to the C-terminal residue S339 (Figure 14C). To 
confirm S339 as PIM1 phosphorylation site on the CXCR4 intracellular C-terminal, 
the phosphorylation reaction was repeated using a similar peptide harbouring a 
S339A mutation (Figure 14C). MALDI-TOF experiments revealed only 
phosphorylation of the wild type peptide but not of the S339A mutant. These results 
strongly suggested that PIM1 regulation of CXCR4 could result from direct 
phosphorylation of the C-terminal domain at S339. A CXCR4 phospho-specific 
antibody has previously allowed the demonstration that phosphorylation of S339 
occurs upon stimulation by CXCl12 by phorbol ester or by EGF (Woerner, 2005). 
This antibody was used in a series of in vitro kinase assays to confirm that PIM1-
dependent phosphorylation of CXCR4 was lost specifically in the S339A mutant but 
not in other mutants (S325A and S330A) corresponding to other putative PIM1 
recognition sites (Figure 14D). To further confirm this finding, we analyzed the effect 
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 of the PIM1 inhibitor on CXCL12-mediated phosphorylation of CXCR4 in 
Jurkat cells. K00486 treatment resulted in a decreased phosphorylation of S339 
comforting our finding that PIM1 is a CXCR4-modyfing kinase in vivo (Figure 14E). 
 Taken together, in a collaborative effort with several groups, we were able to 
demonstrate that in vitro and in vivo transformation of hematopoietic cells is 
independent of PIM2, that PIM1-/- bone marrow cells have an early grafting defect, 
that PIM1 can regulate surface expression and function of the CXCR4 chemokine 
receptor, that PIM1 can modify the intracellular domain of CXCR4, that elevated 
PIM1 levels correlate with surface CXCR4 levels on human AML blasts and that 
blocking PIM reduces surface CXCR4 expression and migration towards a CXCL12 
gradient. 
 
 
 
 
Figure 14: PIM1 phosphorylates the CXCR4 C-terminus at Serine 339. 
A. Confocal immunofluorescence analysis of CXCR4 and PIM1 distribution in Jurkat cells: 
panel D shows a partial co-localization of PIM1 and CXCR4. TOTO-3 was used for nuclei 
staining. 
B. Deletion series defining the CXCR4 C-terminal region phosphorylated by PIM1. 
Schematic representation of human CXCR4 showing the C-terminal 46 amino acids 
expressed as a GST fusion. Three putative PIM1 recognition sites are shown in red. A 
series of C-terminal truncations map PIM1 phosphorylation to a peptide region including 
S339 (indicated by the shaded area). 
C. Identification of S339 as a PIM1 phosphorylation site. MALDI TOF spectra of an 11-mer 
CXCR4 peptide (shaded sequence from B) shows PIM1 phosphorylation of the wild-type 
(WT) sequence but not of a mutant S339A peptide. Box shows detail of the WT 
phosphorylation +/- PIM1 treatment. 
D. In vitro kinase assay performed with different CXCR4 C-terminal mutants confirms that 
CXCR4 is phosphorylated by PIM1 on S339. Protein is detected by anti-PIM1 or anti-
phospho-CXCR4 (Ser339) antibody. 
E. Determination of CXCR4-S339 phosphorylation state in Jurkat cells incubated for 2.5 
hours with CXCL12 (10nM) with or without 1h pre-treatment with the PIM1 inhibitor (10µM). 
S339 phosphorylation is inhibited in presence of K00486 
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 2. Discussion 
 
 Several lines of evidence suggest that the family of PIM serine/threonine 
kinases plays an important role in the pathogenesis of hematological malignancies. 
PIM kinases have been reported as being deregulated by oncogenic protein tyrosine 
kinases (PTK), such as the FLT3-ITD mutant found in up to a third of human AMLs. 
Functional in vitro studies using various cell lines have produced partly conflicting 
results regarding the role of PIM1 or PIM2 (that are both expressed in the 
hematopoietic system) in the pathogenesis of PTK-mediated leukemogenesis 
(Mizuki, 2003; Adam, 2006; Kim, 2005). Our study addressed the role of PIM 
kinases in primary cells and the results showed that transformation of hematopoietic 
cells by FLT3-ITD in vitro and in vivo is independent of PIM2 (Figures 5, 6 & 7A). 
This finding is unexpected, as previous work demonstrated that knockdown of PIM2 
by siRNA, or by expressing dominant-negative “kinase dead” mutants (PIM-KD), 
significantly impaired growth and survival or FLT3-ITD expressing hematopoietic 
cells (Adam, 2006). However, the previous experiments were performed in 
immortalized cell lines that stably express FLT3-ITD, whereas in the present work 
primary mouse bone marrow cells were used. The PIM kinases have been identified 
through serial retroviral gene tagging in c-myc induced lymphomas in wild type as 
well as in PIM knockout mice suggesting that the loss of one PIM can be 
compensated by deregulation of the others (Mikkers, 2002). However, there are 
reports suggesting that in some situations, the loss of a particular PIM kinase may 
not be compensated by the presence of other PIMs. For example, the growth of 
bone marrow derived mast cells from PIM1 knockout animals is significantly reduced 
despite induction of PIM2 by IL-3 (Domen, 1993, Didichenko 2008). Our present 
work clearly demonstrated that in primary murine bone marrow cells expressing 
FLT3- ITD, the lack of PIM1 cannot be compensated by the presence of PIM2. Using 
bone marrow reconstitution assays, we showed that FLT3-ITD induced a lethal 
myelo- and lymphoproliferative disorder in vivo in absence of PIM2. Interestingly, 
PIM1-/- cells expressing an empty retrovirus (MigRI) or FLT3-ITD transplanted in a 
sub-lethally irradiated host, were detectable but gradually declined over several 
weeks post-transplant (Figure 6C). Transplantation of an identical number of PIM1-/- 
cells into lethally irradiated hosts resulted in early death (2-4 weeks) of all recipients 
suggesting that cells lacking PIM1 have an inherent homing defect which was further 
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confirmed in a series of experiments measuring homing to the bone marrow and the 
spleen 4 and 20 hours after transplantation (Figure 8). However, expression of 
FLT3-ITD in bone marrow cells from PIM1-/- mice resulted in generally impaired 
growth in vitro (Figures 5 & 6) indicating that these cells do not only display a 
homing defect but in addition also have a growth disadvantage compared to WT or 
PIM2-/- bone marrow cells. Homing of hematopoietic stem cells (HSCs) to the bone 
marrow niche is a complex and still not well-understood process involving several 
signalling pathways. There is strong evidence that interaction of the chemokine 
CXCL12 expressed on stroma cells with its receptor CXCR4 expressed on HSCs 
plays an essential role in this process (Lapidot, 2005; Juarez, 2004; Burger, 2006). 
Proper functioning of the CXCL12/CXCR4 axis seems to be crucial for directing 
homing/engraftment of normal as well as leukemic HSCs into bone marrow after 
transplantation (Peled, 1999; Tavor, 2004). Our results provide strong evidence that 
PIM1 can functionally regulate CXCR4. Absence of PIM1 is associated with impaired 
CXCL12-induced Ca2+ flux and activation of downstream effectors (Figure 9). In 
addition, functional down-regulation by siRNAs or expression of a dominant-negative 
acting kinase-dead mutant, or treatment with a small molecule PIM kinase inhibitor 
leads to down-regulation of CXCR4 expression at the surface of hematopoietic cells 
(Figures 10-13). In addition, co-localization studies, as assessed by 
immunofluorescence, as well as in vitro kinase assays suggested that PIM1 could 
directly modify the intracellular C-terminal domain of CXCR4 (Figure 14).  
 Our results showed that PIM1 regulates surface expression of CXCR4. PIM1-
/- hematopoietic cells have a subtle but measurable defect in cytokine-mediated 
growth and survival (Domen, 1993, Figure 5). Therefore is very likely that impaired 
in vivo homing of PIM1-/- marrow cells might be the result of inappropriate function of 
several PIM targets including CXCR4. Interestingly, PIM1-/- marrow cells do not 
completely lack CXCR4: in fact, they express less surface CXCR4 most probably as 
a consequence of inappropriate re-expression. As PIM1-/- mice are viable and have 
a normal lifespan, a lower amount of surface CXCR4 seems to be sufficient to 
regulate steady-state hematopoiesis. G protein-coupled receptors like CXCR4 are 
regulated by desensitization, internalization and degradation (Busillo, 2007). CXCR4 
seems to undergo ligand-dependent but also independent internalization and 
surface re-exposure in hematopoietic cells. In both internalization and re-exposure of 
CXCR4, the serine/threonine-rich intracellular C-terminus seems to play a key role 
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 (Orsini, 1999; Pelchen-Matthews, 1999). Natural mutants in patients with 
WHIM syndrome as well as artificial truncation and alanine scanning mutagenesis 
have suggested multiple regions in the CXCR4 C-tail as potential phospho-acceptor 
sites (Hernandez, 2003). However, although multiple protein kinases have been 
proposed (PKC, GRK3, GRK6), no specific kinase has yet been found to be clearly 
implicated (Busillo, 2007). 
 Here, we observed that functional interference of PIM1 led to a decrease in 
CXCR4 surface expression whereas the total amount of the CXCR4 protein remains 
unchanged (Figure 10B). In addition, our work demonstrated that PIM1 regulates 
surface re-expression whereas internalization of the receptor seems not to be 
affected (Figure 13). A similar phenotype has been previously observed in T-cells 
deficient in synaptotagmin 3 (SYT3), although the underlying mechanism remained 
unclear (Masztalerz, 2007). Our experiments using mass spectrometry and in vitro 
kinase assays showed that PIM1 directly phosphorylates Ser339 in the CXCR4 C-
terminal domain (Figure 14). It is worth noting that this site is in a motif that closely 
resembles the consensus PIM recognition motif with -5 arginine and -2 histidine 
although the preferred -3 arginine is absent (Bullock, 2005). The CXCR4 Ser339 is 
known being phosphorylated in brain cancer cells upon stimulation with CXCL12, 
phorbol-ester (PMA) or EGF (Woerner, 2005). Interestingly, both CXCL12/CXCR4 
and EGF/EGFR lead to activation of the JAK/STAT signalling pathway that regulates 
PIM1 expression (Soriano, 2003) while PMA treatment is also known to produce a 
rapid induction of PIM1 expression (Wingett, 1996). As some of the PIM1 target sites 
like the apoptosis regulator BAD (Ser112) or the cell cycle regulator p21 (WAF1) 
(Thr145/Ser146), are also phosphorylated by other protein kinases such as RAF1, 
PAK5, RSK2/5 for the former, and PKC-δ, or AKT for the latter (Aho, 2004; Kim, 
2006; Zhang, 2007), it remains unlikely that PIM1 is the only kinase that 
phosphorylates CXCR4-Ser339. Interaction of CXCL12 with CXCR4 does not only 
provide signals for efficient migration and homing, but seems also to support survival 
of hematopoietic progenitor cells (Lataillade, 2002). There is increasing evidence 
that CXCR4 is a key regulator of homing and retention of leukemic stem cells within 
the marrow niche allowing these cells to escape spontaneous and chemotherapy- 
induced cell death (Juarez, 2004; Burger, 2006). These findings are supported by 
the negative prognostic impact of high CXCR4 expression levels in patients with 
acute myeloid leukemia (Spoo, 2007; Rombouts, 2004).  
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 Consequently, targeting leukemic stem cells within the bone marrow by 
disruption of the CXCL12/CXCR4 interaction by small molecule inhibitors has been 
recently proposed (Juarez, 2007). The association of elevated PIM1 expression with 
expression of high levels of surface CXCR4 in leukemic blasts from AML patients 
(Figure 12A) suggests that targeting aberrant PIM activity by small molecules would 
be rather promising by its effects on interfering not only with self-renewal but also 
with migration and homing of leukemic cells. Indeed, structural analysis of PIM1 has 
allowed us to identify a group of selective small molecule inhibitors with potent anti- 
leukemic activity in vitro (see part III). Short-term treatment of leukemic blasts from 3 
AML patients with the PIM inhibitor (K00486) resulted in a significant decrease of 
steady-state surface CXCR4 expression in two samples (Figure 12B). Ongoing 
experiments aim to understand why some AML blasts are resistant to CXCR4 
regulation after treatment with the PIM inhibitors. Taken together, we have dissected 
the role of PIM serine/threonine kinases for FLT3-ITD leukemogenesis in vitro and in 
vivo. Our work demonstrated that PIM2 is dispensable for transformation by FLT3-
ITD and cells lacking PIM1 are impaired for growth and survival that cannot be 
overridden by FLT3-ITD. Most importantly, our work demonstrated that PIM1 activity 
directs cellular homing and migration by regulation of surface CXCR4. Moreover, 
CXCR4 is also important for homing and maintenance of cancer stem cells, meaning 
that PIM1 inhibitors may exert their anti-tumor effects in part by interfering with 
interactions within the microenvironment. 
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 3. Outlook 
 
 High levels of surface CXCR4 expression have been proposed to be an 
adverse prognostic factor in acute myeloid leukemia (Rombouts, 2004; Spoo, 2007). 
In addition, migration and homing of precursor B-cell acute lymphoblastic leukemia 
(pre-B ALL) cells have been shown to depend on CXCL12/CXCR4 interactions 
(Spiegel, 2004). Interestingly, in this study, pre-B ALL cells express high levels of 
surface CXCR4, yet only low levels of intracellular CXCR4 could be found. In 
contrast, in normal cord blood cells or CD34+ bone marrow cells, most of the CXCR4 
molecules were localized within the cells and only a small fraction was constitutively 
expressed at the surface. In collaboration with Andrea Biondi (Monza), we have 
previously analyzed the expression of PIM kinases in childhood acute leukemia and 
found significant elevated PIM1 levels in over 50% of a panel of more than fifty 
patients (unpublished). These observations raise the possibility that PIM1 
expression might be generally linked to elevated surface CXCR4 expression. In 
order to analyze this possibility, we will compare PIM levels with surface and 
intracellular CXCR4 levels in a larger cohort of human acute leukemia samples by 
flow cytometry and Western blotting in a prospective manner. 
 The CXCL12/CXCR4 signalling axis is not only important for homing and 
migration of hematopoietic stem cells but is a key pathway involved in progression 
and metastasis of several human cancers. Deregulated expression of PIM1 was also 
observed upon progression of a similar spectrum of malignancies including 
carcinomas from prostate, breast or the head and neck region. In order to further 
analyze the link between PIM kinases and the CXCL12/CXCR4 signalling axis, we 
will examine the regulation of surface CXCR4 in prostate cancer in which up-
regulation of PIM1 upon progression has been validated in several studies 
(Dhanasekaran, 2001). We will use four human prostate cancer cell lines (PC3, 
DU145, LNCaP, BHP1, kindly provided by Lukas Bubendorf, Institute for Pathology, 
University Hospital Basel). Previous studies have shown that PC3, LNCaP and 
DU145 express high levels of CXCR4 (Mochizuki, 2004). Interestingly, in preliminary 
experiments, we have observed dose-dependent cytotoxic effects after treatment 
with a PIM1 inhibitor (see below) in PC3, LNCaP and DU145 (derived from 
advanced cancer lesions) but not in BPH1 cells derived from hyperplasia. We will 
first determine steady-state PIM and CXCR4 expression levels by Q-PCR and 
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Western blotting, as well as surface and intracellular CXCR4 expression by flow 
cytometry. Second, CXCR4 levels as well as migration towards a CXCL12 gradient 
will be determined upon blocking PIM function by specific siRNAs, expression of 
PIM-KD mutants or short-term treatment with a PIM inhibitor. These data will provide 
evidence that regulation of migration through modification of the CXCL12/CXCR4 
signalling axis is not limited to leukemic cells but also occurs in solid cancer cells 
expressing PIMs. 
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 III. Targeting PIM kinases with small molecule 
inhibitors: a new avenue for anti-leukemic therapy? 
 
 
1. Results 
 
 Several groups have solved the x-ray crystal structure of PIM1 in complex 
with nucleotid analogs and a number of small molecule ATP-competitive inhibitors 
(Kumar, 2005; Jacobs, 2005; Qian, 2005). Their studies revealed a constitutively 
active kinase conformation of PIM1 in the absence of phosphorylated residues in the 
activation loop. Interestingly, PIM kinases have an atypical hinge region 
characterized by an insertion of one additional residue and the presence of a proline 
that allows formation of only one hydrogen bond with ATP or ATP-mimetic inhibitors 
(Bullock, 2005a; Bullock, 2005b). Probably due to this unique structural feature, all 
potent PIM inhibitors published to date interact with the kinase in an ATP competitive 
but not ATP mimetic binding mode. In close collaboration with two structural biology 
labs (Prof. Stefan Knapp, SGC, Oxford and Prof. Nathanael Gray, DFCI, Boston), we 
have tested several molecular scaffolds that interacted and inhibited PIM kinases in 
cell-free experimental assays (Figure 15). In order to screen for cellular activity of a 
new compound, we used stably transduced murine IL-3 dependent Ba/F3 lympho-
myeloid cells with retrovirus expressing human PIM1, PIM2 or PIM1 and PIM2. As 
PIM over-expression renders these cells growth-factor independent we expected 
that blocking of human PIMs by any inhibitor would impair growth and survival of 
these cells. In case we observed a cellular effect of compound X in these cells, we 
applied these compounds to human leukemia cell lines over-expressing endogenous 
PIMs (e.g. MV4;11, AML with FLT3-ITD and MLL/AF4; or K562, BCR/ABL+, CML in 
blast crisis). We have collected a panel of 15 different human leukemia cell lines 
(K562, MV4;11, RS4;11, MOLM13, PL21, SEM, KOPN8, KCL22, KOCL33, KOCL44, 
KOCL45, JURKAT, THP1, HL60, AML1-USD) that can be tested. In case significant 
cytostatic and/or cytotoxic effects were observed, selected compounds were tested 
for their effects on primary human leukemic blasts. One has to note that freshly 
isolated (or reconstituted frozen) samples of human acute leukemia cells can 
generally only be grown in vitro for a limited period of time in liquid as well as in 
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semi-solid medium (methylcellulose) cultures. In order to obtain any insights about 
general toxicity, we also applied given compounds to human umbilical cord blood 
mononuclear cells or CD34+ cells isolated from healthy donors (kindly provided by 
Prof. Andrea Biondi, Monza, Italy).  
 
 
 
 
 
Figure 15: Validation of novel PIM1 inhibitors in cellular leukemia models in vitro. 
Work-flow for testing cellular efficacy on putative small molecule PIM kinase inhibitors in 
PIM-transformed BaF/3 cells, human leukemia cell lines and primary patient samples. 
Cytotoxic effects on leukemic cells are determined by MTT-analysis. 
 
 
1.1 Imidazo[1,2-b]pyridazines  
 In 2004, a structure activity relationship (SAR) analysis and optimizations of 
imidazo[1,2-a]pyridines as potential cyclin-dependent kinases (CDK) inhibitors were 
described (Byth, 2004). Such inhibitors were expected to be useful as anti-tumor 
agents due to the key role that the CDK enzymes play in controlling the cell cycle. 
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 These compounds were further modified to reduce the lipophilicity of the 
core structure: additional heteroatoms were added into the pyridine ring of the 
imidazo[1,2-a]pyridine and this lead to the identification of imidazo[1,2-b]pyridazines 
(Byth, 2004). Using a structural approach, Prof. Stefan Knapp and co-workers 
reported imidazo[1,2-b]pyridazine to potentially inhibit PIM kinases and showed that 
these compound were around 100-fold more selective for PIM1 over PIM2 (in cell 
free assays), independent of the high sequence homology and conservation of the 
active site. Several imidazo[1,2-b]pyridazines were included in a small kinase-
targeted compound collection obtained from BioFocus (Cambridge, U.K.) biased 
toward simple scaffolds that are prospective low affinity compounds for lead 
development (Bullock, 2005).  
 To understand the structural basis for substrate selectivity by PIM kinases, 
Prof. Stefan Knapp and co-workers resolved the x-ray crystal structure of PIM1 in 
complex with a consensus substrate peptide and the inhibitor K00135 at 1.9Å 
resolution, revealing the kinase with typical bi-lobal architecture and catalytic 
domains positioned in a constitutively closed conformation. The overall structure of 
the protein was found to be similar to structures that have previously been described 
(Kumar, 2005; Bullock, 2005) (Figure 16, kindly provided by S. Knapp). The 
serine/threonine PIM1 kinase has been shown to have a strong preference for 
substrates with basic residues, particularly arginine, at positions -5 and -3 and a 
small side chain at +1. Peptide library screening could define additional selectivity for 
histidine at position -2, proline at -1 and glycine at +1, facilitating the design of a 
high-affinity consensus peptide, pimtide (ARKRRRHPS*GPPTA). As in the case of 
the PIM1-BIM1 peptide complex, the substrate peptide was well defined between 
residues Lys6 and Gly1, whereas the termini were not visible in the electron density 
and assumed to be disordered. Novel kinase inhibitor scaffolds as PIM1 inhibitors 
were established. (Bullock, 2005a; Bullock, 2005b). 
 Although the imidazo[1,2-b]pyridazine inhibitors, such as K00135, bind to the 
ATP-binding site of PIM1, they do not mimic binding of ATP by forming hydrogen 
bonds with the kinase hinge region (shown in pink in Figure 16B) but rather bind to 
the opposite side of the pocket, participating in a hydrogen bond network formed by 
the conserved active site Lys67, a structural water molecule, the αC residue of Glu89 
and the activation loop residue Phe187 (Figure 16). In addition, a number of 
hydrophobic contacts, particularly with PIM1 residues Leu44, Phe49, Ile104, and 
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Leu120, stabilize this interaction. The unusual hinge architecture of PIM1, which has 
a proline at the hinge position 123 allows the formation of only one hydrogen bond to 
ATP or ATP-mimetic inhibitors. Stefan Knapp and co-workers suggested that this 
active site architecture, together with the unexpected binding mode of the studied 
imidazo[1,2-b]pyridazine, could result in surprisingly specific PIM inhibitors. Initial 
screening of a panel of more than 50 diverse serine/threonine kinase catalytic 
domains showed that this scaffold only interacts with another kinase (Cdc-like kinase 
1). A small library of inhibitors based on the imidazo[1,2-b]pyridazine scaffold 
targeting PIM1 kinase was generated and temperature-shift assays were used to 
identify ligands interacting with PIM kinases. This assay monitors the linear affinity-
dependent stability increase of proteins and has been shown to correlate well with 
binding constants and IC50 values (Bullock, 2005). In the study done here, we also 
observed an excellent correlation of temperature shift data (Tm) with in vitro kinase 
assay IC50 values and identified three inhibitors with high potency: K00135, K0486 
and K00152 (Figure 16D). The structure-activity relationship of the library was 
established with two varying positions, R1 and R2. Their crystal structures suggest 
that a large trifluoro-methoxy moiety might favourably interact with the side chain of 
Arg122. 
 
K00135 impairs growth and survival of Ba/F3 cells stably expressing human 
PIMs and human leukemia cell lines. As outlined above, stable over-expression of 
human PIMs renders murine BaF/3 cells growth factor independent. PIM kinases 
have a short cellular half-life, reflected by high levels of human PIM mRNA detected 
(not shown) but only moderate levels of steady-state human PIM proteins could be 
seen. Treatment of the cells with the proteosomal inhibitor MG-132 lead to a 
substantial increase in PIM protein levels (Figure 17A). To address the cellular 
effects of imidazo[1,2-b]pyridazines, we treated BaF/3 cells over-expressing human 
PIMs with different concentrations of the inhibitor, ranging from nanomolar to low 
micromolar levels. Cell survival was determined 24h after treatment by trypan blue 
exclusion. As shown in Figure 17B, for the K00135 compound, a dose dependent 
decrease in viability was observed after 24h in BaF/3-hPIM1 cells growing in 
absence of IL3 whereas BaF/3-hPIM2 cells were less sensitive as expected from the 
higher IC50 values for PIM2 determined for this compound (not shown). 
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Figure 16: Structure of PIM1 in complex with the imidazopyridazine K00135 inhibitor. 
A. Structural overview. The inhibitor and the substrate peptide are shown in ball-and-stick 
representation. (A-C, kindly provided by S. Knapp, SGC, Oxford, UK) 
B. View from the hinge region, highlighted in magenta. (Dotted lines= hydrogen bonds).  
C. Surface representation showing shape complementarity with the active site. 
D. Structure of K00135, K00152 and K00486.
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Despite better potency in in-vitro kinase assays, effects on cell survival using 
K00486 and K00152 were similar. Seven other imidazo[1,2-b]pyridazines showed 
no cellular effects most probably due to a high polarity limiting cellular penetration 
and/or limited solubility (not shown). Importantly, no significant decrease in viability 
was observed in wildtype BaF/3 cells growing in IL3 in the presence of all three 
effective inhibitors tested. In addition, these compounds did not seem to significantly 
interfere with molecules of murine origin that are critical for IL3-mediated cell growth. 
 Cytotoxic effects of K00135, as well as effects on clonogenic growth were 
tested in a panel of human leukemia cells lines: MV4;11, RS4;11, MOLM13, 
KOCL45, SEM, KOP8N and K562. Cytotoxic effects of K00135 were observed in all 
cell lines tested (Figure 18). We also assessed the effect of K00135 on clonogenic 
growth of leukemia cells. Among the tested cell lines, only MV4;11, MOLM13 and 
K562 were able to form distinct colonies (as defined to be composed of >50 cells) 
when plated in methylcellulose. A significant reduction of clonogenic growth was 
observed in MV4;11 and MOLM13 even at inhibitor concentrations lower than 1µM 
whereas colony formation of K562 was no affected even at higher doses as 
expected from the relative resistance of this cell line to this class of inhibitors (Figure 
19, top). To determine the mechanism of K00135-mediated cell death, the induction 
of apoptosis was measured by flow cytometry on MV4;11 cells treated with 1µM 
K00135 using PO-PRO-1, which is a sensitive indicator of apoptotic cells, and 7-
AAD, recognizing dead cells. The percentage of apoptotic MV4;11 cells increased in 
a time-dependent manner, with 2.8% of cells undergoing apoptosis and 15.3% dead 
after 12h and 8.5% apoptotic and 40.5% dead cells after 36h of treatment (Figure 
19, bottom). 
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Figure 17: Effect of K00135 on BaF/3 cells stabely expressing human PIMs. 
Increasing amounts of K00135 were added to MV4;11 and RS4;11 and other cell lines and 
cell viability, as well as IC50 values were determined 24h and 48h later (IC50 values were 
determined using the Cell Proliferation Reagent WST-1 from Roche). 
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Figure 18: Effect of K00135 on human leukemia cell lines. 
Increasing amounts of K00135 were added to MV4;11 and RS4;11 and other cell lines and 
cell viability, as well as IC50 values were determined 24h and 48h later (IC50 values were 
determined using the Cell Proliferation Reagent WST-1 from Roche). 
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Figure 19: Effect of K00135 on leukemic cells. 
A. Effect of K00135 on clonogenic growth of leukemia cell lines in methylcellulose.  
B: MV4;11 cells were grown in the presence of 1µM K00135 for indicated amount of time. 
Apoptosis was analyzed with 7-AAD (indicator of dead cells) and PO-PRO-1 (sensitive 
indicator of apoptotic cells) followed by flow cytometric analysis. Representative quadrants 
from analysis are shown. 
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In vitro effect of K00135 on primary human leukemic blasts. When leukemic 
blasts from five patients with newly diagnosed AML (kindly provided by Dr. Sandrine 
Meyer, Department of Hematology, University Hospital Basel) were cultured in 
methylcellulose, formation of typical small leukemic cell clusters (<50 cells) was 
observed (Figure 20B). These could not be analyzed by classic quantitative colony 
forming assays. However, exposure of leukemic blasts to K00135 in a short-term 
culture resulted in a significant decrease in survival for all patient samples. Although 
K00135 showed an effect on colony formation of all primary cells analyzed, no 
significant difference in survival was observed between the patients harbouring 
FLT3-ITD mutation (patients 1 and 2) and those without (patients 3-5) (Figure 20A). 
Cytotoxic effects of K00135 were also tested on normal human cord blood cells at 
anti-leukemic doses. In this experiment, only a minor effect on the survival of normal 
umbilical mononuclear cells was noticed (Figure 20C).  
 
Effect of K00486 on prostate cancer cells. Several previous reports showed 
elevated expression of PIM1 in biopsies of prostate tumours related to the grade and 
neoplastic transformation of the prostate carcinomas (Xu, 2005; Dhanasekaran, 
2001; Chen, 2005). In order to test cellular effects of imidazo[1,2-b]pyridazines on 
prostate cells, we applied these compounds to four different human prostate 
carcinoma cell lines (PC3, LNCAP, DU145 and BPH1). In contrast to Ba/F3 cells, 
these cells grow as single adherent layers in Petri dishes. We treated the cells with 
different concentrations of K00486 for 48h. A dose-dependent decrease in viability 
was observed in all cell lines. Interestingly, BPH1 cells originating from a prostate 
hyperplasia were less sensitive to K00486 than LNCaP or PC3 cells, originally 
isolated from bone marrow metastasis of a high-grade adeno-carcinoma (Figure 
21). It is of interest to note that optimized cellular effects could only be obtained 
when the cells were plated at low to mediated density (22’500 cells/cm2). These 
results showed that imidazo[1,2-b]pyridazine inhibitors have in vitro cytotoxic activity 
not only in leukemia but also in prostate cancer. 
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Figure 20: K00135 impairs in vitro survival of primary leukemic blasts. 
A. Leukemic blasts from five patients were grown in liquid cultures with or without increasing 
amounts of K00135 and cell viability was determined 24h later (expressed as a percentage 
and normalized to the viability of cells treated with 0.1% DMSO only). 
B. When cultured in methylcellulose in the presence of K00135, significantly lower density of 
characteristic small leukemic clusters were observed, compared to control cultures. 
C. Cytotoxic effects of K00135 were analyzed in liquid cultures of umbilical vein-derived 
mononuclear cells from four healthy donors and cell viability was determined as a 
percentage compared with the viability of cells treated with 0.1% DMSO only.
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Figure 21: Effect of K00486 on prostate cancer cell lines. 
Increasing amounts of K00486 were added to four prostate cancer cell lines 24h after plating 
and the viability was determined as percentage compared to the viability of cells treated with 
DMSO only (trypan blue exclusion). 
 
 
Effect of imidazo[1,2-b]pyridazine inhibitors (K00135) on phosphorylation of 
PIM1 substrates. To show that PIM1 kinase activity is indeed affected by K00135 in 
leukemic cells, we monitored the phosphorylation status of its downstream targets by 
immunoblotting using phospho-specific antibodies. The anti-apoptotic protein BAD 
has been shown to be serine phosphorylated by both PIM1 and PIM2 (Kim, 2006; 
Macdonald, 2006). To show inhibition of PIM1 activity in MV4;11 cells, PIM protein 
was immunoprecipitated and analyzed for its ability to phosphorylate BAD on Ser112 
and Ser136 in vitro in the presence (1h) or absence of 2µM K00135. As shown in 
Figure 22B, phosphorylation of BAD by PIM1 and PIM2 was abrogated in the 
presence of K00135. To further analyze the effects of K00135 on PIM function, 
phosphorylation of two known direct PIM targets (BAD and 4E-BP1) was followed by 
immunoblotting. Short-term exposure of the cells to 1µM K00135 led to a significant 
decrease of BAD and 4E-BP1 phosphorylation (Figure 22C). In contrast, no 
changes were observed in phosphorylation of AKT (not shown). These results 
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 suggested that K00135 indeed blocks PIM kinases in MV4;11 cells, 
however off-target effects on currently unknown proteins cannot be excluded. 
 
 
 
 
Figure 22: K00135 impairs phosphorylation of known downstream PIM  targets. 
A. Schematic representation of the in vitro kinase assay. 
B. PIM proteins were immuno-precipitated from MV4;11 cells and the agarose-protein A-
immuno-precipitate complex was tested for its ability to phosphorylate BAD in vitro in the 
presence or absence of K00135. (Asterisks = heavy chain of the anti-PIM2 rabbit antibody 
recognized by the anti-rabbit IgG secondary antibody) 
C. MV4;11 cells were incubated with 1 µM K00135 for indicated times, harvested and 
protein extracts separated by SDS-PAGE. The effect of K00135 on PIM endogenous targets 
was followed by Western Blotting with indicated phospho.specific antibodies 
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1.2 Beta-carbolines  
 β-Carboline alkaloids are a large group of natural and synthetic indole 
alkaloids with different degrees of aromaticity, some of which are widely distributed 
in nature, and found in various plants, foodstuffs, marine creatures, insects, 
mammalians as well as human tissues and body fluids. These compounds are of 
great interest due to their diverse biological activities. Particularly, some of these 
compounds have been shown to intercalate into DNA, to inhibit CDK, 
Topoisomerase, and monoamine oxidase, and to interact with benzodiazepine 
receptors and 5-hydroxy serotonin receptors. Furthermore, some of these chemicals 
also demonstrated a broad spectrum of pharmacological properties including 
sedative, anxiolytic, hypnotic, anti-convulsant, anti-tumor, anti-viral, anti-parasitic as 
well as anti-microbial activities (Cao, 2007).  
 By using temperature-shift screening, where ligand binding is simply detected 
as a relative increase in the protein’s melting temperature, and cell-free in vitro 
kinase assays, Prof. Stefan Knapp and co-workers identified several β-carboline 
derivates (named as AMTC, Carb2, Carb10 and Carb13) as powerful small molecule 
PIM kinase inhibitors in cell free assays (Figure 23, kindly provided by S. Knapp). 
We tested some of these compounds for their activity in our leukemia cell models. 
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 Figure 23: Structure of PIM1 in complex with the beta-carboline Carb13 
inhibitor. 
Structural overview: the main secondary structure elements and the NH2 and COOH termini 
of the protein are labelled. The inhibitor and the substrate peptide are shown in ball-and-
stick representation (provided by S. Knapp, SGC, Oxford, UK). 
 
 
 
In vitro cellular effect of Carb13 on Ba/F3-PIM cells, human leukemic cell lines 
and primary AML blasts. To investigate the potential cellular anti-leukemic activity 
of the carboline PIM inhibitors, the most promising compound Carb13 was tested for 
effects on growth and survival of the murine Ba/F3 cells transformed to IL-3 
independency by over-expression of human PIMs. Exposure of the cells to different 
concentrations of Carb13 resulted in a dose-dependent reduction of cell survival 
after 48h of treatment (Figure 24A). Carb13 was more effective in Ba/F3-PIM1 than 
in Ba/F3 over-expressing human PIM2. However, in contrast to the K00135 
imidazo[1,2-b]pyridazine (Figure 17), strong affection of parental Ba/F3 cells 
growing in presence of IL-3 was also observed. The reason for this strong activity in 
parental Ba/F3 cells is currently unclear, but could indicate some unspecific toxicity 
of this compound. 
 Cytotoxic effects of Carb13, as well as effects on clonogenic growth were 
furthermore tested in several human leukemia cells lines (MV4;11, RS4;11, 
MOLM13, SEM, K562). Treatment of the cells with different concentrations of 
Carb13 impaired growth of all cell lines in liquid culture with calculated IC50 values 
ranking from 2.07µM (MV4;11) to 6.49µM (K562) (Figure 24B). In analogy to 
K00135, cell lines harbouring the oncogenic FLT3-ITD mutation, like MV4;11 or 
MOLM13, were more sensitive than K562 cells that originate from BCR/ABL-positive 
blast crisis patient.  
 The effect of Carb13 on the growth of leukemic blasts from patients with 
newly diagnosed AML was also analyzed. When cultured in methylcellulose, cells 
from AML patients grew in small clusters (Figure 24D). Forty-eight hours after 
addition of Carb13, a strong reduction in cell survival was observed. Exposure of 
leukemic blasts to Carb13 in liquid culture also resulted in a significant decrease in 
survival: treatment with 5µM Carb13 resulted in a 50% reduction of surviving cells 
when compared to the control (DMSO). However, exposure of mononuclear cord 
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blood cells from two healthy donors to Carb13 at anti-leukemic doses affected 
cellular survival in a similar manner than for the AML cells (Figure 24C). These 
observations demonstrated that although Carb13 has significant anti-leukemic 
activity, this compound exerts strong cytotoxic effects also on normal hematopoietic 
cells. 
 
 
 
Figure 24: Evaluation of the biological activity of Carb13. 
A. Ba/F3 wild-type (WT) cells and stably expressing hPIM1 and/or hPIM2 cells were 
exposed to increasing amounts of Carb13 and cell viability was determined 48h later 
(expressed as a percentage normalized to viability of cells treated with 0.1% DMSO only). 
B. Carb13 IC50’s were determined in different human cell lines after 48 hour-treatments. 
C. Leukemic blasts from three patients and umbilical vein–derived mononuclear cells from 
two healthy donors were grown in liquid cultures without or with increasing amounts of the 
drug, and cell viability was determined 48 h later.
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D. Example of leukemic blasts cultured in methylcellulose in the presence of Carb13, 
significantly lower density of characteristic small leukemic clusters was observed as 
compared with control cultures. 
 
 
Effect of Carb13 on the phosphorylation of PIM1 downstream targets. In order 
to obtain some insights in Carb13 action on PIM kinase activity in vivo, we analyzed 
the phosphorylation status of the known PIM substrates such as BAD and 4E-BP1 
by immunoblotting using phospho-specific antibodies (Figure 25). As PIM1 has 
recently been proposed to be regulated by AKT kinase, we also included this kinase 
in the analysis (Muraski, 2007). MV4;11 cells were incubated for 30, 90 and 180 
minutes with different concentrations of Carb13. During this short time period, no 
adverse cellular effects were observed. Whole cell lysates were prepared and 
separated by gel electrophoresis. Treatment of MV4;11 with Carb13 was associated 
with decreased phosphorylation of BAD as well as 4E-BP1 suggesting that cellular 
PIM1 was indeed blocked by this compound (Figure 25). Rather unexpected, it was 
also observed that Carb13 treatment reduced phosphorylation of AKT that has never 
been characterized as PIM substrate.  
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Figure 25: Effect of Carb13 
on the phosphorylation of 
PIM1 downstream targets. 
A. In vitro Bad 
phosphorylation by PIM 
kinase was evaluated in the 
presence of increasing 
concentrations of Carb13. 
Phosphorylation of BAD on 
Ser112 was detected by 
Western blotting with 
phospho-specific antibody. 
B. MV4;11 cells were 
incubated with increasing 
concentrations of Carb13  
for indicated times, harvested, and protein extracts separated by SDS-PAGE. The effect of 
Carb13 on PIM endogenous targets was followed by Western blotting with indicated 
phosphospecific antibodies. 
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1.3 Other potential PIM inhibitors tested  
Quercetin. Quercetin, a member of the flavonoid family, is one of the most 
prominent dietary antioxidants. It is ubiquitously present in food including vegetables, 
fruits, tea and wine as well as countless food supplements and is claimed to exert 
beneficial health effects. This includes protection against various diseases such as 
osteoporosis, certain forms of cancer, pulmonary and cardiovascular diseases but 
also against aging (Boots, 2008). Especially the ability of quercetin to scavenge 
highly reactive species such as peroxynitrite and the hydroxyl radical is suggested to 
be involved in these possible beneficial health effects. Consequently, numerous 
studies have been performed to gather scientific evidence for these beneficial health 
claims as well as data regarding the exact mechanism of action and possible 
toxicological aspects of this flavonoid. It has been demonstrated that quercetin 
treatment of prostate cancer cells results in decreased cell proliferation and viability 
(Boots, 2008; Aalinkeel, 2008). Furthermore, quercetin promotes cancer cell 
apoptosis by down-regulating the levels of heat shock protein (Hsp) 90. Depletion of 
Hsp90 by quercetin results in decreased cell viability, levels of surrogate markers of 
Hsp90 inhibition (intracellular and secreted), induced apoptosis and activation of 
caspases in cancer cells but not in normal prostate epithelial cells (Aalinkeel, 2008) 
 By screening a kinase targeted compound library, Stefan Knapp and co-
workers found quercetin to be a high-affinity inhibitor of PIM1 (Bullock, 2005). We 
tested quercetin on our BaF/3 cells over-expressing PIMs, as well as on BaF/3 cells 
over-expressing the leukemia associated TEL/JAK2 and FLT3-ITD PTK (leading to 
increased PIM1 and PIM2 expression) (Figure 26). We could observe that the 
survival of all BaF/3 cells decreased in a dose-dependent manner, in liquid culture, 
as well as in methylcellulose, as shown here for BaF/3 WT and BaF/3 PIM1. Based 
on the findings from Aalinkeel et al. as well as on those from Russo et al. showing 
that quercetin enhances CD95- and TRAIL-induced apoptosis in leukemia cell lines, 
these results suggested that quercetin is most likely not a PIM1 specific inhibitor: the 
observed effects are most probably the result of targeting other molecules such as 
Hsp90 (Aalinkeel, 2008; Russo, 2007). 
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Figure 26: Evaluation of the biological activity of Quercetin. 
A. Ba/F3 wild-type (WT) cells and stably expressing hPIM1, hPIM2, FLT3-ITD and Tel/JAK2 
cells were exposed to increasing amounts of Quercetin and cell viability was determined 48 
h later (expressed as a percentage normalized to viability of cells treated with 0.1% DMSO 
only). 
B. Example of leukemic blasts cultured in methylcellulose in the presence of Quercetin. 
Significantly lower density of characteristic small leukemic clusters was observed as 
compared to control cultures.  
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New Furan compounds. The core scaffold of these compounds is furan, a 
heterocyclic organic compound. These compounds were discovered as potential 
PIM1 inhibitors by Prof. Nathanael Gray and co-workers from the Dana Farber 
Cancer Institute (Boston, USA). Originally, these furan scaffolds were generated to 
produce inhibitors for cyclin-dependent kinases (CDKS) or PI3K (Pomel, 2006; 
Richardson, 2007). Identifying them as PIM1 inhibitors was achieved by using the 
interaction platform provided by Ambit Biotechnology (San Diego, USA) including a 
panel of over 400 human kinases (www.ambit.com). The initial screen was followed 
by structure activity relationship (SAR) analysis to select putative PIM inhibitors with 
cellular activity. In analogy to the imidazo[1,2]pyridazines, these inhibitors interact 
with the opposite site of the PIM1 ATP binding pocket, without making significant 
polar contacts with the kinase hinge region. 
 We recieved 15 compounds that were shown to interact with PIM1 in the 
Ambit screen. To investigate the potential cellular anti-leukemic activity of these 
compounds, we tested them on the parental murine BaF/3 cell line as well as on 
Ba/F3 cells transformed to IL-3 independency by over-expression of human PIMs for 
effects on growth and survival. As a control, the cells were also treated with K00135. 
Exposure of the cells to different concentrations of 5 out of 15 of these compounds 
resulted in a dose-dependent reduction of cell survival (Figure 27). 
 
 
 
 
 
 
 
Figure 27: Evaluation of the biological activity of the new furan compounds (pages 66-
68). 
Ba/F3 wild-type (WT) cells and cells stably expressing hPIM1 and hPIM2 were exposed to 
increasing amounts of furan compounds and cell viability was determined 24 and 48 hours 
later with trypan blue exclusion (expressed as a percentage normalized to viability of cells 
treated with 0.1% DMSO only). The most potent compounds (cvm-6-039, cvm-6-061, cvm-5-
149-3, cvm-6-060-2 and cvm-6-060-3) are highlighted in red. K00135 served as a control for 
all the experiments. 
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2. Discussion 
 
 Our group and others have shown that aberrant expression of PIM kinases in 
hematopoietic cells transformed by oncogenic protein tyrosine kinases provide a 
strong rationale for development of PIM kinase inhibitors as potential therapeutic 
targets (Amson, 1989; Nieborowska-Skorska, 2002; Kim, 2005; Adam, 2006). Using 
a combined structure functional approach in collaboration with Prof. Stefan Knapp 
(University of Oxford, UK) and Prof. Nathanael Gray (Dana Farber Cancer Institute, 
Boston, USA), we have characterized a group of small molecules that interact and 
block PIM kinases in vitro and in vivo. One of the imidazo[1,2]pyridazines 
compounds referred as K00135 significantly reduced the growth and self-renewal 
capacity of several human and leukemic cell lines as shown by inhibition of their 
clonogenic activity (Figures 18, 19). Furthermore, exposure of primary blasts from 
five AML patients to the K00135 inhibitor leads to a significant reduction in cell 
survival and clonogenic growth. Interestingly, exposure of mononuclear cells from 
human cord blood from four healthy donors to the compound was associated with 
minimal cytotoxic effects (Figure 20). These observations suggest that K00135 
interacts with aberrant PIM activity found in cancer but not in normal cells. These 
observations go along with the finding that mice lacking all known PIM kinases are 
fertile and have a normal life span, suggesting that PIMs may not be essential for 
steady-state homeostasis, although deregulated upon malignant transformation 
(Mikkers, 2004). Biochemical analysis strongly suggests that our compound indeed 
blocks PIM1 function and its downstream targets such as BAD or 4E-BP1. However, 
a current potential drawback of the identified compound might be that significant 
reduction of growth and survival of human leukemia cell lines or primary samples 
could only be achieved at relatively high concentrations in the micromolar range. 
 Although almost all major pharmaceutical companies invest in generating 
small molecule PIM inhibitors, only a few have been published by academic labs 
(Tong, 2008; Jacobs, 2005; Cheney, 2007; Holder, 2007a; Holder, 2007b). All PIM 
inhibitor structures that have been published to date interact with the kinase hinge 
region in a classic ATP mimetic way.  
 Our imidazo[1,2]pyridazine PIM inhibitors result from screening of a kinase-
targeted library and structure-activity relationship analysis. Related inhibitors of the 
pyrazolpyrimidine class were first described as specific inhibitors of the Src family of 
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tyrosine kinases, with several pyrazolo[3,4d]pyrimidines having low nanomolar 
affinity for Lck and anti-cancer activity (Hanke, 1996). Subsequently, similar 
scaffolds yielded specific inhibitors for glycogen synthase kinase 3 and members of 
the cyclin-dependent kinase (CDK) family (Markwalder, 2004).   
 However, all published co-crystal structures of this inhibitor class show 
binding to the kinase hinge region in the expected type I binding mode, meaning 
they target the ATP binding site in its active conformation in which the activation loop 
is phosphorylated. In the case of the imidazo[1,2]pyridazines, another binding mode 
was identified, in which the inhibitor interacts with the opposite site of the ATP 
binding pocket, without making significant polar contacts with the kinase hinge 
region. In addition, the conserved Asp-Phe-Gly (DFG) motif in the active site did not 
move into an “out” conformation as observed in co-crystal structures of kinases with 
type II inhibitor complexes. However, the described area of the binding pocket is 
much more diverse than the hinge region, bearing the promise that more specific 
inhibition may be developed on the basis of the determined crystal structure.  
 In a first temperature shift assay-based screen covering 50 serine/threonine 
kinases, Knapp and co-workers observed significant cross-reactivity of K00135 with 
only a few other kinases such as Cdc-like kinase 1 (CLK-1). The CLK kinase family 
acts as an interface between signal transduction pathways and the splicing 
machinery in the nucleus but a role in cancer has not been described yet (Duncan, 
1997). With the huge number of continuously generated new scaffolds, identification 
of potential targets using high-throughput interaction screens becomes one of the 
main activities in modern drug discovery. To screen interactions of new scaffolds 
with the human kinome, AMBIT Biosciences (San Diego, USA) has developed a 
platform (referred as KINOMEscan) to study interactions of currently >400 
members of the human kinome (Fabian, 2005; Karaman, 2008; www.ambit.com). 
This assay is based on competition binding that quantitatively measures the ability of 
a compound to compete with an immobilized, active site directed ligand. Each assay 
is performed in combining three components: DNA-tagged kinase domain, 
immobilized ligand and a test compound. The ability of the test compound to 
compete with the immobilized ligand is measured via quantitative PCR of the DNA 
tag (Fabian, 2005 & Figure 28). Although one has to keep in mind that in vitro 
interaction in this assay does not necessarily means in vivo inhibition, screening a 
large number of compounds that are either in clinical use (e.g. Imatinib-mesylate, 
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Gleevec) or in clinical trials (e.g. VX-680/MK0457) has nevertheless provided 
important insights that could help to explain cellular effects of small molecule kinase 
inhibitors. Based on the structural homology of certain kinases (“targets”), it is not 
surprising that only very few compounds are indeed selective. Interestingly, even 
imatinib-mesylate interacts with about 10 different kinases such as ABL, PDGFR, or 
KIT (Figure 28). Through collaboration with Prof. Nathanael Gray (Dana Farber 
Cancer Institute, Boston, USA) it was possible to perform a KINOMEscan analysis 
with the K00135 compound.  
 Interestingly, as listed in the table below, on the AMBIT platform, K00135 
interacted with at least ten other kinases, some even with a higher affinity than PIM1 
(unpublished). Among them, also wildtype and mutant targets (e.g. FLT3-ITD, 
mutant KIT) that are known drivers in leukemogenesis were found. However, one 
has to keep in mind the limitations of this assay that addresses binding, but not 
inhibition. Target affinities cannot be quantified directly since binding is reflective not 
only of affinity, but also abundance of the target. In addition, direct and indirect 
interactions that can occur in a cell cannot be distinguished. 
 
 
 
 
 
 
 
 
 
 
 
Figure 28: The KINOMEscan platform from AMBIT Biosciences. 
A. Schematic representation showing hoe KINOMEscan works (adapted from Fabian, 2005). 
B. Small molecule-kinase interaction map for 38 kinase inhibitors. Kinases found to bind are 
marked with red circles, where larger indicate higher-affinity binding. Interactions with Kd < 
3µM are shown (Kd, binding constant). Compounds with a bold edge are mentioned in this 
discussion part (adapted from Karaman, 2008). 
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Table 1: Potential targets for K00135 found in the KINOMEscanassay. 
Only the ones with Kd<5 are shown. As in Figure 28, the lower the Kd, the tighter the binding 
(Kd, binding constant).  
 
 
 The KINOMEscan analysis of K00135 might help to explain some of our 
observations when testing its cellular activity. Increased cytotoxicity of K00135 to 
MV4;11 when compared to RS4;11 might be explained by the presence of a driver 
FLT3-ITD mutation present in MV4;11 but not in RS4;11 leukemia cells. The same 
observations were made very recently for another compound: PKC-412, currently 
tested as FLT3 inhibitor has been shown to inhibit PIM1 in cell lines and AML cells 
(Xie, 2008). Despite the limited specificity, the biology of the K00135 recognized 
targets suggests that this scaffold could nevertheless be a promising lead for further 
optimization. Among the potential targets of K00135 are ACVR1, a TGFbeta 
receptor kinase, MKNK2 or PDGFRbeta, all well known for their role in malignant 
transformation (Grisaru, 2007; Silva, 2008; Massague, 2008). In conjunction with our 
finding that inhibition of PIM1 will also functionally impair CXCR4 signaling (see 
chapter II), we suggest that our imidazo[1,2]pyridazines are potent leads for targeted 
therapeutics against leukemic stem cells (Juarez, 2004). Indeed, several 
imidazo[1,2]pyridazines have been recently patented to be used as cancer 
therapeutics and one related imidazo[1,2]pyridazine compound, referred as SGI 
1776, produced by SuperGen Inc. (Dublin, California, USA) shows potent anti-
leukemic activity and could enter in phase I clinical trials (www.supergen.com). 
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 Large-scale temperature-shift analysis and in vitro kinase assays performed 
in Prof. Knapp’s laboratory also resulted in the identification of a new class of 
potential PIM kinase inhibitors: the beta-carbolines. Beta-carboline alkaloids are a 
heterogenous group of natural and synthetic indole alkaloids widely distributed in 
nature (plants, marine creatures, insects, human body). These compounds have 
recently gained interest due to their biological activity as neuromodulators and 
potential cancer drugs (Cao, 2007). Among 4 carbolines (AMTC, Carb2, Carb10 and 
Carb13), Carb13 was selected for further testing for its activity in leukemia cell 
models. Like K00135, Carb13 impaired growth and survival of Ba/F3 cells 
transformed to IL-3 independence by over-expression of human PIM1 (Figure 24). 
In contrast to K00135, Carb13 also strongly affected growth and survival of the 
parental Ba/F3 cells growing in the presence of IL-3. This is rather surprising, as 
previous siRNA-PIM knockdown experiments in Ba/F3 cells did not result in severely 
impaired cell survival (Adam, 2006). The observed effects on parental Ba/F3 cells 
are therefore most probably the result of interaction with other unknown targets 
(kinases or other molecules). Like K00135, Carb13 was also impairing proliferation 
of a panel of human acute leukemia cell lines, as well as primary cells from 3 
patients with de novo acute myeloid leukemia. However, in contrast to K00135, 
Carb13 also strongly affected growth and survival of umbilical cord blood 
mononuclear cells from healthy donors. This observation together with the results 
observed in Ba/F3 cells strongly suggest that Carb13 has cytotoxic properties that 
might be independent of PIM kinases. Indeed, immunoblotting for known PIM targets 
and other signalling molecules showed that although Carb13 reduced 
phosphorylation of known PIM substrates (BAD, 4E-BP1) in MV4;11 cells, it also 
affected others such as the AKT kinase (Figure 25) that has been proposed to act 
upstream of PIM1 but not to be a direct substrate (Muraski, 2007). Although Carb13 
has previously been tested in temperature-shift interaction screens against 60 
human kinases to be rather specific (data not shown), our observation suggests that 
Carb13, like K00135, may target other kinases that are essential for cellular growth 
and survival. Interestingly, several carboline derivates have been recently 
characterized as potent inhibitors of protein kinases involved in cell survival (e.g. 
IkBa kinase, IKK) and/or proliferation (cyclin-dependent kinases, CDKs) (Castro, 
2003). Despite the strong interaction and inhibition of PIM kinases by Carb13, further 
large-scale screening for potential targets (e.g. by using the AMBIT KINOMEscan 
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platform) as well as chemical modification of the compound would be necessary to 
obtain a potential lead PIM inhibitor (Fabian, 2005). Currently, Carb13 is undergoing 
extensive testings as anti-cancer drug at the National Cancer Institute (NCI, 
Bethesda, MD, USA). 
Using the KINOMEscan approach, Prof. Nathanael Gray and his group 
have identified several furan scaffolds as potential PIM1 inhibitors. These 
compounds harbor a similar binding mode than the imidazo[1,2]pyridazines and 
were originally identified as cyclin-dependent kinase inhibitors (Pomel, 2006; 
Richardson, 2007). Five (out of 15 so far characterized) showed potent cytotoxic 
effects when tested in our BaF/3 cells over-expressing human PIMs. Similar to 
Carb13, the cytotoxic effects of the 5-149-3 furan were not limited to BaF/3-PIM cells 
but also affected wild-type Ba/F3 cells (Figure 27), again suggesting that these 
effects might be mediated by the recognition of other targets. Indeed, a 
KINOMEscan analysis of 5-149-3 showed interactions with a large number of 
potential targets including AURORA, ABL, FLT3, KIT, and others. This compound is 
currently crystallized in complex with PIM1 by Prof. Stefan Knapp and his group. 
Taken together, the imidazo[1,2]pyridazine compounds (K00135, K00486 or 
K00512) recognizing a limited number of kinase targets were the more promising 
scaffolds with potent anti-leukemic activity and limited toxicity to normal cells.  
Although previous studies have shown that an optimal PIM-targeted tumor therapy 
would include inhibition of PIM1 and PIM2 (Mizuki, 2003; Hammerman, 2005; Adam, 
2006), thus far, there is no selective potent inhibitor for PIM2 available, suggesting 
that PIM2 is intrinsically more difficult to target. This finding is surprising considering 
the high sequence conservation of the PIM1 and PIM2 active sites. This reveals a 
kind of isoform selectivity suggesting that dynamic parameters like domain flexibility 
and plasticity of regulatory elements should be considered in structure-based 
inhibitor design (Fedorov, 2007). 
 As PIM kinases have been intensively characterized as proteins of relative 
weak inherent oncogenicity but potent in cooperation with other oncogenes such as 
c-myc (Shirogane, 1999; Moroy, 1993), it is likely that synergistic effects may be 
achieved in combination with either conventional chemotherapeutics and/or small 
molecules that target cooperating signaling cascades linked to survival of the 
malignant cells. (Shay, 2005; Mizuno, 2001). 
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 The success for establishing new targeted leukemia (or cancer in general) 
therapies through small molecule kinase inhibitors is dependent on several general 
points. First, and most important, the biology of the disease that is affected by 
aberrantly activated kinases that are potential drug targets. Chronic 
myeloproliferative disorders such as CML or polycythemia vera (PV) are both driven 
by one or a limited number of mutated and constitutively activated kinases such as 
ABL, JAK2, PDGFR. Inhibition of these drivers by small molecules such as imatinib-
mesylate (Gleevec) has revolutionized CML therapy (Druker, 2002; Quintas-
Cardama, 2005). However, in contrast, acute leukemia is the product of several 
cooperating driver mutations affecting different pathways and therefore it is likely that 
selective targeting of one kinase might not necessarily be successful. This is 
currently best illustrated by the results of first clinical trials with very potent and 
selective small molecule FLT3 inhibitors targeting mutant FLT3 found in about 30% 
of human AML. Several studies have shown that the depth and duration of clinical 
responses to FLT3 inhibitor monotherapy have been modest (Small, 2008). 
Furthermore, a number of mechanisms by which blasts may acquire resistance have 
been proposed. Based on preclinical evidence of synergy with conventional 
chemotherapy, several combination trials are now underway (Knapper, 2007). 
 Based on these observations, inhibitors that would block several cooperating 
pathways essential for growth and/or survival of the leukemic cells would be ideal. 
However, dissecting of critical targets remains a major challenge of modern cancer 
research. Several clinical trials attempting treatment of acute leukemia with multi-
kinase inhibitors (such as sorafenib or sunitinib) are currently ongoing. In spite of 
this, an increased number of targets recognized by a given compound is naturally 
linked to an increase of potentially not tolerable side-effects. Modern large-scale 
interaction screens such as the KINOMEscan from AMBIT provided important 
information regarding the limited selectivity of most small molecule kinase inhibitors 
currently in clinical trials but limited selectivity of a compound might also be an 
advantage: it seems that it is the combination of targets recognized by Gleevec 
including ABL, KIT and PDGFR that makes this drug the first choice to treat CML, 
gastrointestinal stromal tumors, or systemic mastocytosis driven by activating 
mutation of ABL, PDGFR or KIT. Interestingly, this target combination seems also to 
be responsible for efficacy in CML therapy (Wong, 2004). In addition, large-scale 
interaction screens also resulted in the identification of new potentially important 
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targets. VX680 initially developed as inhibitor of Aurora kinases could be identified 
as powerful inhibitor of BCR/ABL-T315I a mutant linked to Gleevec resistance 
(Giles, 2007). However, the relatively large number of recognized kinases by VX680 
could also explain the strong adverse effects that were observed in first clinical trials: 
these were stopped due to cardiotoxicity (www.clinicaltrials.gov).  
 In collaboration with Prof. Stefan Knapp’s laboratory we have characterized 
LY-333’531 (Figure 28), a compound initially generated as inhibitor of PKC-β as 
potent inhibitor of PIM1 (Fedorov, 2007). Our findings are further supported by the 
AMBIT KINOMEscan showing, among others, a strong interaction with PIM1. It is 
interesting to note that this compound has previously been in clinic as a drug 
(Ruboxistaurin) against long-term renal and eye complications of diabetes mellitus 
(Ravera, 2007; Ryan, 2007). Our observations of potent anti-leukemic activity of this 
well tolerated compound could open up some therapeutic possibilities. A derivate of 
LY-333’531, called LY-317’615 or Enzastaurin (Eli Lilly and Company) and also 
inhibiting PKC-β would also have been a potential candidate compound to inhibit 
PIM1 but the company declined our request to perform some tests. 
 Taken together, research of the last decade has provided evidence that 
aberrant activity of protein kinases is an important driver of a large number of human 
malignancies including leukemia. Much progress has been made in developing 
powerful small molecule inhibitors such as Gleevec, targeting constitutively activated 
tyrosine kinases driving CML. Further improvements for kinase inhibitor-based 
leukemia therapy will be dependent on identification of critical signalling pathways 
affected by collaborating protein kinases (e.g. FLT3-PIM1-CXCR4), and the in vitro 
and in vivo validation of compounds blocking the ideal number of targets with 
tolerable side effects.  
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3. Outlook 
 
 There is evidence that targeted therapy of leukemic cells harbouring an 
oncogenic PTK (such as FLT3-ITD or BCR/ABL) with small molecule tyrosine kinase 
inhibitor leads to an initial induction of PIM1 expression. Moreover, cellular hypoxia 
also leads to induction of PIM1 kinase expression (Reiser-Erkan, 2008). These 
observations suggest that the cells use PIM kinases to maintain survival upon 
external stress and raise the question whether it would be possible to enhance the 
cytotoxic effect of the small molecule PIM kinase inhibitors in combination with other 
(targeted or untargeted) cytotoxic agents. In order to experimentally address this 
question, we will select human leukemia cell lines harbouring either the FLT3-ITD 
(MV4;11, MOLM13) or BCR/ABL (K562) mutations. PIM inhibitors can then be 
combined to PKC412, a specific FLT3 inhibitor, or with imatinib-mesylate that 
efficiently blocks the ABL1 PTK. Furthermore, we will combine the PIM inhibitors 
with conventional anti-leukemic agents, like doxorubicin or etoposide. These agents 
will be applied either by (i) co-incubation, (ii) sequential incubation or (iii) pre-
incubation with the cooperating compound. Previous reports testing combination of 
PTK inhibitor with conventional chemotherapeutic drugs have identified synergestic 
cytotoxic effects upon sequential application, additive effects upon co-treatment and 
antagonistic effects when treatment with the kinase inhibitor started earlier (Jacinto, 
2008). Taken together, these in vitro experiments will help to select the most 
promising PIM inhibitor for further analysis in vivo. 
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IV. A transgenic mouse model to study the role of 
NUP214/ABL1 in T-cell ALL 
 
 
1. Background 
 
 In T-cell acute lymphoblastic leukemia (T-ALL), several transcription factors 
(such as TAL1, SIL, LMO2, HOX11, HOX11L2) were shown to be deregulated by 
chromosomal translocations mostly involving the T-cell receptor genes (TCR), 
whereas activating mutations in protein tyrosine kinases have rarely been identified 
(Pui, 2004; Rabbitts, 1994). The Philadelphia translocation, resulting in the 
BCR/ABL1 fusion gene is typically found in chronic myeloid leukemia (CML) and 
precursor B-cell acute lymphoblastic leukemia (B-ALL) but very rare in T-ALL. In 
2004, Graux and co-workers described an extra-chromosomal episomal 
amplification of ABL1 in 6% of T-ALL patients (Graux, 2004). Molecular analysis 
delineated the amplicon as a 500kb region from chromosome band 9p34, containing 
the oncogenes ABL1 and NUP214 (Figure 29). This transcript was detected in five 
individuals with ABL1 amplification, in 5 of 85 additional individuals with T-ALL and in 
3 of 22 T-ALL cell lines (Graux, 2004). Like BCR/ABL1 and ETV6/ABL1 fusion 
proteins, NUP214/ABL1 fusions contain the SH3, SH2 and kinase domains of ABL1, 
and were shown to act as a constitutively activated tyrosine kinase, activating similar 
pathways than BCR/ABL1. This constitutively phosphorylated tyrosine kinase is also 
sensitive to the tyrosine kinase inhibitor imatinib (De Keersmaecker, 2008). As 
already mentioned in the introduction, constitutively active tyrosine kinases have 
been shown to be sufficient to induce myeloproliferative disease in mice but require 
the cooperative effect of other mutations to induce acute leukemia. In agreement 
with this, additional mutations were identified in cells expressing the NUP214/ABL1 
fusion. Deletion of the tumor suppressor genes CDKN2A and CDKN2B (also called 
p15 and p16) were found in seven of nine cases evaluated. Screening for 
oncogenes known to be involved in T-ALL identified the mutually exclusive 
expression of HOX11 and HOX11L2 (Graux, 2004; Ballerini, 2005; Ballerini, 2008). 
Similar results were seen in T-ALL cells lines, where for example expression of 
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HOX11 was found in ALL-SIL. These results are consistent with a multi-step 
pathogenesis of T-ALL (Graux, 2004). 
 
 
 
Figure 29: The NUP214/ABL1 fusion. 
A. Extrachromosomal amplification of ABL1 identified with the LSI BCR/ABL1 probe (Vysis) 
in interphases and in one metaphase. Normal chromosomes 22 (BCR) and one normal 
chromosome 9 are indicated. The other chromosome 9 carries a deletion of ASS, FUBP3 
and ABL1. Nine to fifteen extra copies of ABL1 are observed. 3’ ABL1, LAMC3 and NUP214 
are amplified, whereas ASS, FUBP3, 5’ ABL1 and VAV2 are not. CDKN2A shows a 
heterozygous deletion. 
B.  Detailed scheme of the amplified (circularized) region, and the proposed structure of the 
episome. Genes (arrows), BAC clones (gray bars), and their positions along chromosome 9 
are indicated. Cen, centromeric site; Tel, telomeric site. 
C. Schematic representation of the NUP214 and ABL1 proteins. Two main NUP214/ABL1 
fusion proteins are generated: a shorter fusion (239kDa) present in only one individual, and 
longer fusions (310-333kDa) present in most individuals with T-ALL with ABL1 amplification.  
This figure has been generated using figures from Graux, 2004. 
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2. Results 
 
2.1 Generation of a NUP214/ABL1 transgenic mouse mode 
 In order to understand the role of the NUP214/ABL fusion for the 
pathogenesis of T-cell ALL in vivo, we aimed to generate a transgenic mouse model. 
Hereby, the NUP214/ABL1 cDNA was cloned in a conventional transgene vector 
bringing the fusion under the control of the Lck proximal promoter (Figure 30A).  
Lck is a specific lymphocyte protein tyrosine kinase regulating allelic exclusion at the 
T-cell receptor β, used regularly for transgenes inducing hematological malignancies 
(Aifantis, 2008; Condorelli, 1996). We performed SfiI digestion to release the insert 
purified the DNA which was then injected into fertilized oocytes of C57Bl/6 mice at 
the Transgenic Mouse Core Facility at the Biozentrum (University of Basel). To our 
surprise, we had to perform several injections to obtain viable offspring enabling us 
to identify 2 NUP214/ABL1-positive founders. The presence of the NUP214/ABL1 
transgene was assessed by PCR with a primer pair localized over the fusion 
breakpoint on genomic DNA (Figure 30B). Two transgenic mouse lines could be 
established.  
 
2.2 Analysis of the NUP214/ABL1 transgene expression 
 As the NUP214/ABL1 fusion is under the Lck promotor, we analyzed transgene 
expression in the thymus of young mice of both lines. We could detect mRNA expression of 
the fusion in the thymus of the mice, what correlated with the use of the LCK promoter. No 
expression was seen in the spleen and bone marrow (Figure 31A). Successful attempts to 
generate transgenic mouse models for T-ALL were all characterized by a long latency 
period until the disease developed. We followed the mice once a week over a period of 18 
months. However, I have not observed any signs of disease. I also analyzed the blood 
counts of three transgenic mice of both lines at different time points and compared it to 
blood counts of wild type C57Bl/6 mice but we could find no significant differences in white 
blood cell counts or any other parameters (Figure 31B). We then analyzed the distribution 
of T-cells in the thymus of an eighteen-month-old mouse from the first transgenic line and 
compared it to the thymus of wild type mouse in the same age range by FACS analysis. 
Again, there were no significant differences between these two mice regarding the 
distribution of T cells, as demonstrated by FACS analysis (Figure 31C).
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Figure 30: Generation of a NUP214/ABL1 transgenic mouse model. 
A. Schematic representation of the experimental setup. 
B. Detection of the NUP214/ABL1 transgene expression on isolated toe DNA with a 
primer pair over the breakpoint (red arrows). An actin PCR was done as control. 
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 As no phenotype has been seen, we analyzed the copy number of 
NUP214/ABL1 in each line by Q-PCR. One line expresses 59 copies and the 
other one 86 copies of the transgene. We are still working on the Western Blot 
as for technical reasons, we could not detect the NUP214/ABL1 protein, even 
in a cell line over-expressing the fusion. 
 Taken together we have generated two transgenic mouse lines 
expressing low levels of NUP214/ABL in the T-cell lineage that did neither 
resulted in measurable disturbance of T-cell development nor induction of a 
haematological malignancy over a period of 18 months.  
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Figure 31: Analysis of the NUP214/ABL1 transgene expression. 
A. Detection of the NUP214/ABL1 transgene expression on thymus cDNA of three different 
mice: one positive founder, his negative brother and an unrelated normal B6 mouse. The 
band present in the RT- slot of the positive founder is believed to be the NUP214/ABL1 
fusion. 
B. Peripheral blood analysis of three transgenic mice of each strain (strain 1: mice 2, 26, 80; 
strain 2: mice 7, 40, 50) compared to wildtype B6 mice analyzed at Jackson Laboratories. 
C. T-cell status analysis in a NUP214/ABL1 transgene mouse compared to a 
wildtype B6 mouse, both 18 months old.  
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3. Discussion 
 
 Approximately 15% and 25% of the newly diagnosed cases of acute 
lymphoblastic leukemia in childhood and adults are T-cell ALL and are 
generally linked with a poor prognosis. T-ALL is thought to result from 
malignant thymocytes that arise at defined stages of intra-thymic T-cell 
differentiation (De Keersmaeker, 2005). Several studies have shown that the 
NUP214/ABL1 fusion is associated in about 5-10% of human T-ALL cases 
(Graux, 2004; Quintas-Cardama, 2008). In order to study the role of the 
NUP214/ABL episomal amplification or single copy fusion for the 
pathogenesis of T-cell ALL, we have created transgenic mice expressing the 
NUP214/ABL1 fusion in the T-cell lineage using a T-cell specific promoter 
(Lck). This promoter is among the most frequently used for transgene 
expression in T cells, including the p56lck proximal promoter (Allen, 1992), a 
promoter based on the human CD2 locus control regions and promoters 
derived from the CD4 and CD8 genes. The p56lck promoter is expressed in 
early T cell progenitors and can be detected in DN T cells. The p56lck 
promoter is not well characterized and might be susceptible to modulations, 
depending on where it gets integrated into the genome (Cantrell, 2002). This 
could explain why we got only two positive founders after in vitro fertilization. 
Another possibility could be that too many copies of the transgene were lethal 
and that only mice expressing low levels of the fusion survived. The second 
possibility is more likely as over-expression of protein tyrosine kinase has 
been shown to be problematic for the generation of transgenic mouse models 
(Cantrell, 2002). 
 There are many mouse models of T-cell leukemia, but many of them 
do not develop leukemia, or if so, then after a long latency confirming the 
multi-step pathogenesis of the disease. Seo et al. created Cdt1 transgenic 
mice using the p56lck promoter and these mice showed normal T-cell 
development, meaning that Cdt1 over-expression under the p56lck promoter 
was not sufficient for T cells to acquire growth advantage. When they crossed 
these transgenic mice into p53-/- mice, the offspring developed thymic 
lymphoblastic leukemia (Seo, 2005). Graux et al. and others also found that 
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additional mutations were found in cells expressing the NUP214/ABL1 fusion. 
Some of these mutations involved the homeobox genes HOX11 and 
HOX11L2 (Graux, 2004; Ballerini, 2005; Graux, 2008). Homeobox genes are 
master regulators of transcription first identified for their function in early 
development and are strongly implicated in the regulation of hematopoiesis 
(Aifantis, 2008). From these, only HOX11 and HOX11L2 have been 
associated with T-ALL (Su, 2006). The HOX11 gene was originally identified 
because it was found to be involved in the t(10;14) translocation found in 7-
10% of pediatric patients with T-ALL, and subsequently, was also found to be 
involved in the t(7;10) translocation. In addition, the expression of this gene is 
frequently up-regulated in T-ALL cells in the absence of a genetic re-
arrangement. Importantly, the HOX11 gene is normally not expressed in 
thymocytes, but during leukemogenesis, its expression can become controlled 
by the regulatory regions of the TCR loci, thereby inducing aberrant 
expression in T cells and causing a block at the DP stage. However, over-
expression of HOX11 alone is also not sufficient to induce leukemia (Aifantis, 
2008). Retroviral infection of the NUP214/ABL1 mice with HOX11 or 
HOX11L2 virus would perhaps have resulted in a leukemia phenotype. 
Another possibility why we do not see any effect in the NUP214/ABL1 
transgenic mice is that there might not be a simple linear correlation between 
transgene copy number and protein expression for any transgene promoter. 
The level of protein expression is regulated by rates of gene transcription, but 
not infrequently, the rate of protein translation and protein stability are of equal 
importance in determining steady-state protein levels. The stability and half-
life of proteins is often not that relevant when they are massively over-
expressed in transient transfection assays, but become crucial under more 
physiological conditions (Cantrell, 2002). 
 Recently, De Keersmaeker et al. found that the NUP214/ABL1 fusion is 
a relatively weak oncoprotein (when compared to BCR/ABL), relying on 
incorporation into the nuclear pore complex and interactions with other 
nuclear pore proteins for its kinase activation and oncogenicity. They could 
also explain why the NUP214/ABL1 gene is always amplified in T-ALL, as the 
NUP214/ABL1 protein has to compete with endogenous NUP214 for nuclear 
pore localization (De Keersmaecker, 2008). This could also explain why our 
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transgenic NUP214/ABL1 mice show no leukemic phenotype, even after a 
long latency. However, as the NUP214/ABL1 also occurs as non-amplified 
translocation, this observation might explain episomal amplification. It does 
not rule out that in other cases, this fusion needs cooperation of other 
alterations to induce the disease. Nevertheless, based on the findings of De 
Keersmeacker et al., decreasing the gene dosage of NUP214 (e.g. by 
crossing with NUP214+/- mice, or by siRNA) could be another possibility to 
induce the disease.  
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4. Outlook 
 
 There are many mouse models of T-cell leukemia that do not develop 
leukemia, or if so, then after a long latency confirming the multi-step 
pathogenesis of the disease. In order to obtain a leukemic phenotype from our 
NUP214/ABL1 transgenic lines, we planed to combine this fusion to other 
cooperating events known to play a role in the pathogenesis of leukemia. We 
thought of three different strategies:  
1. Based on the lastest findings of De Keersmaecker et al., another way of 
inducing a leukemic phenotype in the NUP214/ABL1 transgenic mice would 
be to reduce the dose of endogenous NUP214 using a specific murine siRNA 
(De Keersmaecker, 2008). 
2. As shown by Seo et al., crossing Cdt1 transgenic mice showing no T cell 
leukemia phenotype into p53-/- mice resulted in T-ALL (Seo, 2005). We could 
cross our mice into p53-/- mice or into p15-/- or p16-/- mice, as p15 and p16 
tumor suppressor genes are involved in leukemo- and lymphomagenesis. 
3. As HOX11 and HOX11L2 are known to be involved in T-ALL, we could 
perform bone marrow transplantations with HOX11- or HOX11L2-retrovirally 
infected NUP214/ABL1 cells. One abstract from the upcoming American 
Society of Hematology (ASH) meeting even suggests that HOX11L2 
rearrangement and loss of p15 precede the formation of the NUP214/ABL1 
fusion and subsequent amplification (Pisecker, 2008). This could be 
considered if our strategies do not result in the induction of a leukemic 
phenotype. 
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V. Material and methods 
 
 
1. Material 
 
Cell lines 
 
293T  Human embryonal kidney 
293  Human embryonal kidney 
BaF/3  Mouse pro-B cell 
Jurkat  Human T-cell leukemia 
PC3  Human prostate carcinoma 
DU145 Human prostate carcinoma 
BPH1  Human benign prostate hyperplasia 
LNCAP Human prostate carcinoma 
ALL-SIL Human T-cell leukaemia 
RS4;11 Human B cell precursor leukaemia 
MV4;11 Human acute monocytic leukaemia 
MOLM13 Human acute myeloid leukaemia 
K562  human chronic myeloid leukemia in blast crisis 
SEM  Human B cell precursor leukaemia 
 
 
Inhibitors 
 
Imidazo[1,2-b]pyridazines   Stefan Knapp 
Beta-carbolines    Stefan Knapp 
Quercetin dihydrate    Sigma 
Furan compounds    Nathanael Gray 
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Antibodies 
 
Mouse monoclonal α-FLAG   Sigma 
Mouse monoclonal α-HA (12CA5)  Roche  
Rabbit polyclonal α-HA    Santa Cruz  
Mouse monoclonal α-Pim1   Santa Cruz Biotechnologies  
Mouse α-Human β-Actin    Sigma 
Rabbit polyclonal α-CXCR4   Abcam  
Rabbit polyclonal α-NUP214   Novus Biologicals 
Mouse monoclonal α-c-ABL1   Santa Cruz Biotechnologies 
Alexa Fluor 488 goat α-rabbit   Molecular Probes 
Alexa Fluor 555 goat α-mouse   Molecular Probes 
APC-rat IgG2β,κ Isotype control   BD Biosciences 
PE-rat IgG2β,κ Isotype control   BD Biosciences 
FITC-rat IgG2β,κ, Isotype control   BD Biosciences 
Rat α-mouse CXCR4, biotinylated  BD Biosciences 
Streptavidin-APC conjugate   BD Biosciences 
APC-mouse monoclonal α-human CXCR4 BD Pharmingen 
PE-rat monoclonal α-mouse CXCR4  BD Pharmingen 
PE anti-mouse CD4 (L3T4)   BD Pharmingen 
PE anti-mouse CD45    BD Pharmingen 
PE anti-mouse CD8     BD Pharmingen 
FITC anti-mouse CD8    BD Pharmingen 
FITC anti-mouse TCRβ    BD Pharmingen 
APC anti-mouse TCRβ    BD Pharmingen 
APC anti-mouse CD4    BD Pharmingen 
 
 
Patient samples 
 
Patient samples were gifts from A. Biondi (Monza) and from S. Meyer-Monard 
(University Hospital Basel). 
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Primers 
 
NUP214 fwd   GGT CAA GCA GCC AGT ACT GG 
ABL1 rev   GCT TAG AGT GTT ATC TCC ACT GGC C 
NUP/ABLf-SYBR  CAG CCA ACA AAA ACC CAT TCA 
NUP/ABLR-SYBR  TCC AAC GAG CGG CTT CAC 
mActin fwd SYBR  CCA TAG GCT TCA CAC CTT CCT G 
mActin rev SYBR  GCA CTA ACA CTA CCT TCC TCA ACC G 
mJak2 fwd SYBR  CCA CGG CCC AAT ATC AAT G 
mJak2 rev SYBR  CCC GCC TTC TTT AGT TTG CTA 
 
 
Mice 
 
FVB/NJ WT  M. Nawijn, The Netherlands Cancer Institute, Amsterdam
    Jackson Laboratories 
FVB/NJ PIM1-/- M. Nawijn, The Netherlands Cancer Institute, Amsterdam 
FVB/NJ PIM2-/- M. Nawijn, The Netherlands Cancer Institute, Amsterdam 
B6   Animal facility, University Hospital Basel 
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2. Methods 
 
Transient transfection of 293T cells and retrovirus production 
The day before, 3.106 cells were plated per 10cm dish in 10mL of 
DMEM complete. The day of transfection, 10µg of DNA (5µg packaging 
plasmid IPAC6 and 5 µg plasmid of interest) were dissolved in DMEM 
containing no antibiotics or serum to a total volume of 300µL. 70µL of Polyfect 
was added, the solution was mixed and incubated for 10min at room 
temperature. During this time, the medium was removed from the cells and 
7mL of fresh DMEM complete was added. After incubation, 1mL of DMEM 
complete was added to the transfection complexes; the solution was mixed by 
pipeting up and down twice and the total volume was immediately transferred 
to the cells. Plates were swirled to ensure uniform distribution of the 
complexes and incubated for 48h and/or 72h at 37º. 
After 24h, the cell culture medium was changed. After 48h, the virus 
was harvested using a syringe and sterilely filtered through a 0.45µm millipore 
filter, aliquoted in 2mL tubes on ice and concentrated at 14000rpm, 1h at 4º. 
Approximately 1.8mL of supernatant was removed and the rest was carefully 
re-suspended, pooled together and stored on ice for cell transduction 
experiments. 
 
Transduction and transplantation 
 Bone marrow was harvested from FVB/N [wild-type (WT)], FVB/N 
PIM1-/-and FVB/N PIM2-/- donor mice and incubated overnight in IMDM/ 20% 
FCS supplemented with growth factors (10ng/ml mIL-3, 10ng/ml mIL-6, 
50ng/ml mSCF). Cells were transduced in 4 rounds of spin infection (1200g, 
32°C, 90min) with 4µg/ml polybrene (Sigma). Subsequently, cells were 
resuspended in Hanks´ balanced salt solution (Sigma-Aldrich, Irvine, UK) and 
injected into the tail vein of sub-lethally (750rad) or lethally irradiated (900rad) 
FVB/N recipient mice. All procedures were reviewed and approved by the 
University’s supervisory animal care committee. 
 
In vitro colony-forming assays 
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 Bone marrow was transduced following the method described in 
“Transduction and transplantation of murine bone marrow”. 10-20x103 EGFP-
positive bone marrow cells per well were plated in triplicate in methylcellulose 
media containing recombinant IL3 (10ng/ml) or no cytokines (StemCell 
Technologies, Vancouver, Canada). 
 
Histology 
Tissue samples from PIM1-/-, PIM2-/- and wild type FVB/NJ mice were 
fixed in 4% paraformaldehyde, paraffin-embedded and 4µM sections were 
stained with Haematoxiylin-Eosin (this was done at the pathology). Pictures 
were taken at 50 and 200 fold magnifications using a Zeiss microscope. 
 
Flow cytometric immunphenotyping (FACS-analysis) 
 Single-cell suspensions of indicated tissue samples were prepared by 
passing tissue through 100µm nylon mesh strainers (Falcon, Becton-
Dickinson, Heidelberg, Germany). Red blood cells of peripheral blood were 
lysed prior to analysis. Cells were pre-incubated with Fc-block and CD45-
PECy5 and subsequently stained with either PE-conjugated anti CD11b (Mac-
1), CD45R/B220, CD90.1 (Thy1.1), CD4 or CD8α antibodies as indicated. 
Dead cells were excluded by propidium iodide (PI), or 7-amino-actinomycin D 
(7-AAD) staining as mentioned in the text. Cell surface expression of CXCR4 
was analyzed by staining with PE-conjugated anti-mouse CD184 (2B1) or 
APC conjugated anti-human CD184 (12G5) antibodies (Pharmingen, Becton-
Dickinson). Unspecific binding was assessed by a PE- or APC-conjugated rat 
IgG2b isotype control. Fc-block and all antibodies were purchased from BD 
Pharmingen, Heidelberg, Germany. 
 
Bone marrow cell homing 
Recipient FVB/NJ mice were lethally irradiated (900rad) prior to 
transplantation. Donor cells from PIM1-/- or wild type FVB/NJ mice were re-
suspended at 106 cells/mL in pre-warmed PBS/0.1%BSA and stained with 
1µM CFSE (Molecular Probes) for 10min at 37º. The reaction was stopped by 
adding 5 volumes of ice-cold medium and a 5min incubation on ice. The cells 
were then washed three times in PBS and re-suspended in an appropriate 
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volume for injection. Mice received 1.106 CFSE-positive cells in 100µL 
solution via tail vain injection. Comparable staining as well as viability was 
determined by FACS analysis. Mice were killed 4 or 20 hours post-
transplantation. Single cell suspension of bone marrow and spleen were 
made and the cells were stained with APC-conjugated anti-CD45 antibody 
and the dead cells excluded by 7AAD staining. The gates were set on CD45-
positive cells and CFSE-positive cells were detected at 517nm. 
 
Bone marrow cell migration 
5.105 bone marrow cells from PIM1-/- and wild type FVB/NJ mice were 
allowed to migrate four hours toward a 300ng/mL SDF1α gradient using 
transwell chambers (5.0µm pore size, Costar). Cells found in the bottom 
chamber were counted and the migration index was calculated as a 
percentage of input cells. The same experiment was done with BaF/3 cells 
and Jurkat cells. Here, the migration was done toward a 10nM SDF1α 
gradient for four hours using the same transwell chambers. In some of the 
experiments, the cells were first pre-treated with 10µM K00486 for two hours. 
 
Determination of intracellular Ca2+ flux 
 Freshly isolated bone marrow cells were loaded with 1µM Fura-2-AM 
(Molecular Probes) in calcium buffer (137mM NaCl, 2.7mM KCl, 1.8mM 
CaCl2, 1mM MgCl2, 5.6mM Glucose, 0.1% BSA and buffered with 20mM 
HEPES at pH7.4). After incubation at 37º for 10min, the cells were washed 
twice and re-suspended in calcium buffer to a final concentration of 2.106 
cells/mL. Fura-2 fluorescence was monitored in an LS50B luminescence 
spectrophotometer (Perkin Elmer). The excitation wavelengths used were 340 
and 380nm; the emission was measured at 510nm. [Ca2+]I was calculated 
from the Grynkiewicz equation. The Kd used was 224nM. Rmax was obtained 
after lysis of the cells with 0.1% Triton X-100 and Rmin was determined by 
addition of 10mM EDTA 
 
Treatment of Jurkat, cells with the PIM1 inhibitor K00486 
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 Jurkat cells were splitted the day before. For the experiment, 105 cells 
were plated in 2mL RPMI complete per well of a 24-well plate. The PIM1 
inhibitor K00486 was diluted to a 5mM concentration in DMSO and 4µL were 
given to each well. 0.1% DMSO was used as a negative control. After 
different time points, cells were harvested, resuspended in 200µL PBS and 
incubated with the APC α-human CXCR4 antibody for 30min on ice in the 
dark. FACS analysis was performed on a FACSaria from BD. 
 
CXCR4 expression after PIM inhibition in AML patient samples 
 Mononuclear cells from peripheral blood from AML patients with more 
than 90% of leukemic cells were freshly purified using Ficoll gradient. Cells 
were washed in PBS and seeded in 24-well plates with 106 cells per ml media 
containing RPMI and 10% FCS. Cells were treated with DMSO, 5 or 10 µM 
K00486. After 30 min of treatment cells were fixed in 3.75% PFA and CXCR4 
surface expression was measured using APC-conjugated anti-human CD184 
(12G5) antibody. 
 
Quantitative RT-PCR analysis 
 mRNA expression was determined by quantitatitve real-time PCR (RT-
PCR) using SYBRGreen. 1µg of total mRNA (isolated with the RNeasy kit, 
Qiagen, Hilden Germany) was used for cDNA synthesis (High Capacity cDNA 
Reverse Transcription kit, Applied Biosystems), and 50ng cDNA was applied 
for RT-PCR using the Power SYBR Green PCR Mastermix (Applied 
Biosystems) on an ABI Prism 7700 sequence detection system (Applied 
Biosystems). Expression levels were normalized to glyceraldehyd-3-
phosphate dehydrogenase mRNA (GAPDH) using the ΔCt method. The 
following oligonucleotides were used as PCR primers: hPIM1-forward, 5’-cga 
gca tga, cga, aga gat cat-3’, hPIM1-reverese, 5’-tcg aag gtt ggc cta tct ga-3’ 
(119bp amplicon); hCXCR4-forward, 5’-atg aag gaa ccc tgt tcc cgt-3’, 
hCXCR4-reverse, 5’-aga tga tgg agt aga tgg tgg g-3’ (76bp amplicon); 
hGAPDH-forward, 5’-gtg gtc tcc ctg act ttc aac agc-3’, hGAPDHreverse, 5’-atg 
agg tcc acc acc tgc ttg ctg-3’ (149bp amplicon). Statistical significance was 
assessed by one-way ANOVA. 
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Regulation of CXCR4 surface expression 
 JURKAT cells were plated in RPMI complete at a concentration of 
105/mL and pre-treated for one hour with 10µM K00486 or DMSO at 37ºC, as 
indicated. After this treatment, cells were incubated for 30 min or 60 min with 
10nM SDF1α at 37ºC. Half of the cells were washed three times in PBS to 
remove CXCL12 and K00486 and resuspended in new medium. The rest was 
left in the original medium. Samples were collected right after the CXCL12 
treatment and 1, 2 and 3 hours after washing. Cells were fixed in 4% PFA. 
Surface CXCR4 was analyzed by staining with APC-conjugated anti-human 
CD184 (12G5) antibody. Non-specific binding was determined by using the 
APC-conjugated rat IgG2b as isotype control (BD Pharmingen). 
Cytospins and confocal microscopy analysis 
 Jurkat cells were fixed with 4% paraformaldehyde for 15min at room 
temperature and flattenend on a glass slide. The cells were washed twice with 
PBS and incubated for 10min in 1% Trition X-100. After three PBS washings, 
they were treated with 1mg/mL Rnase A. The Rnase was washed away by 
washing three times with PBS and the cells were then incubated with Image-
iT FX signal enhancer (Molecular Probes) for 15min and blocked 10min in 
1%BSA + 0.1% Tween in PBS. After extensive washing, cells were incubated 
with the primary antibody for one hour, at a 1:100 dilution in blocking solution. 
The cells were then washed five times with PBS and incubated for one hour 
with the secondary antibody (1:500, in the dark). Nucleus staining was done 
with propidium iodide for 10min at a concentration of 2.5µg/mL. The cells 
were washed again and mounted in 30µL FluorSafe Reagent (Calbiochem). 
Confocal microscopy was carried on a LSM 510 laser scanning microscope 
from Zeiss. 
 
Phosphorylation of GST-CXCR4 
 PIM1 was expressed and purified as described previously (Bullock, 
2005). GST-CXCR4 fusions were expressed in BL21 (DE3) cells with 0.5mM 
IPTG induction for 6 hours at 18°C. Cells were lysed using a high-pressure 
homogenizer, cleared by centrifugation and the lysates purified by glutathione 
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sepharose chromatography. Phosphorylation reactions were performed for 90 
minutes at room temperature in 125µl samples containing 1µM PIM1 and 
10µM GST-CXCR4 buffered in 50mM HEPES pH 7.5, 100mM NaCl, 1mM 
DTT, 1mM ATP, 5mM MgCl2, 1Mm MnCl2. Control samples were treated 
similarly in the absence of PIM1. Reactions were stopped by the addition of 
0.1% formic acid and protein masses determined by ESI-LC/MS, using an 
Agilent LC/MSD TOF system with reversed-phase HPLC coupled to 
electrospray ionization and an orthogonal time-of-flight mass analyzer. 
Proteins were desalted prior to mass spectrometry by rapid elution off a C3 
column with a gradient of 5-95% acetonitrile in water with 0.1% formic acid. 
Spectra were analyzed using the Agilent Protein software. 
 
In vitro kinase assay 
 5µg recombinant PIM1 was incubated at 30°C for 5 min in kinase 
buffer [40mM Tris-HCl (pH7.4), 20mM MgCl2, 0.1mg/mL bovine serum 
albumin] containing 500µM ATP with or without 2mM PIM inhibitor (K00486) 
(51). 8µg of mentioned GST-CXCR4 construct were then added for further 10 
min. The reactions were terminated by the addition of Laemmli sample buffer, 
and phosphorylation of CXCR4 was analyzed by Western blotting with anti-
phospho-CXCR4 antibody (kindly provided by J. Rubin, St. Louis, USA). 
 
Treatment of transformed BaF/3 cells with PIM inhibitors 
BaF/3 cells were plated at a concentration of 2.105 cells/mL in a 24 well 
plate (1mL/well). PIM inhibitors were diluted to the appropriate concentrations 
in DMSO. A further dilution of the inhibitors in cell culture medium was 
performed at a ratio 2:1000 (inhibitor:medium). 1mL of this dilution was then 
given to each well of cells and the plates were incubated for 24h and 48h at 
37º. After 24h and 48h, cells were harvested and counted using trypan blue 
exclusion. 
 
Treatment of human cell lines with PIM inhibitors 
Human cell lines were plated at a concentration of 2.105 cells/mL in a 
24 well plate (1mL/well). PIM inhibitors were diluted to the appropriate 
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concentrations in DMSO. A further dilution of the inhibitors in cell culture 
medium was performed at a ratio 2:1000 (inhibitor:medium). 1mL of this 
dilution was then given to each well of cells and the plates were incubated for 
24h and 48h at 37º. After 24h and 48h, cell proliferation and viability were 
assayed using 100µL of the culture and 10µL of Cell Proliferation Reagent 
WST-1 (Roche Diagnostics). After 4h in the cell culture incubator, plates were 
read with the Spectra Max 190 and data were analyzed with the Softmax Pro 
software. 
 
Treatment of AML samples with PIM inhibitors 
Samples were defrosted and cultured for 2h in AIM-V medium 
(Cambrex) supplemented with 10% FCS, 1 mmol/L L-Glutamine and 1% 
Pen/Strep. Cells were either used for colony forming assays, as described 
below, for FACS analysis (as described for human cell lines) or for viability 
tests. Cells were plated at a concentration of 2.105 cells/mL in a 24 well plate 
(1mL/well). PIM inhibitors were diluted to the appropriate concentrations in 
DMSO. A further dilution of the inhibitors in cell culture medium was 
performed at a ratio 2:1000 (inhibitor:medium). 1mL of this dilution was then 
given to each well of cells and the plates were incubated for 24h and 48h at 
37º. After 24h and 48h, all the cells were harvested and re-suspended in 1mL 
medium. Counting was performed using trypan blue exclusion. 
 
In vitro colony forming assay 
AML sample cells (105) were given to 2 mL of human complete 
methylcellulose supplemented with PIM inhibitor and plated in 35mm Petri 
dishes for 10 days at 37º. Light microscopy was done to assess colony 
formation. 
 
Protein extraction and Western blotting 
 MV4;11 cells were grown at 5 x 105/mL, treated with 1 to 3µM K00135 
for various times, harvested, and rinsed with ice-cold PBS. Ice-cold lysis 
buffer [10 mM Tris-HCl (pH 7.4), 150mM NaCl, 1% Triton X-100, 0.5mM 
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EDTA, 10% glycerol, 10mM NaF, 1 mM Na3VO4, protease inhibitor cocktail] 
was added to the cells, incubated on ice for 20min and followed by 5min 
centrifugation. Proteins were precipitated from supernatant using methanol-
chloroform and pellets were re-suspended in Laemmli's sample buffer, 
separated by SDS-PAGE, and transferred to the membranes. The 
membranes were blotted with primary antibodies (diluted according to the 
manufacturer's recommendations), followed by horseradish peroxidase–
conjugated secondary antibodies, and the proteins detected by SuperSignal 
West Femto Maximum Sensitivity Substrate (Pierce). The same blots were 
stripped and re-probed with desired antibodies to confirm equal loading. 
Immunoprecipitation and in vitro kinase assay. 
  Cell lysates from 2 µM K00135-treated MV4;11 cells (60 min) were 
prepared as described above and incubated with either no antibodies or 2µg 
of anti-PIM1 antibody with gentle rocking at 4°C overnight. Protein A-agarose 
beads (Upstate; 50µL of 50% beads slurry in 500µL of the lysate) were added 
and incubated for additional 2h, followed by 15s centrifugation, three washes 
with 300mM lysis buffer, and two additional washes with kinase buffer [40mM 
Tris-HCl (pH 7.4), 20mM MgCl2, 0.1mg/mL bovine serum albumin]. Beads 
were then suspended in 50µL of kinase buffer supplemented with 500µM ATP 
and either no inhibitor or 2 µM K00135 and incubated at 30°C for 30min. Four 
micrograms of soluble BAD protein (Upstate) were then added to the reaction 
and incubated for additional 30 min. The reactions were terminated by 
addition of Laemmli sample buffer and phosphorylation of BAD was analyzed 
by Western blotting using anti–phospho-BAD (Ser112/136) antibodies. 
 
Preparation of the NUP214/ABL1 construct for injection 
The p1017 NUP214/ABL1 plasmid was a gift from J. Cools. 100µg 
were digested with SfiI to release the NUP214/ABL1 insert, loaded on a gel, 
the right band was cut out and the DNA extracted with a purification kit. The 
injection was performed into fertilized oocytes of C57Bl/6 mice at the 
Transgenic Mouse Core Facility from the Biozentrum. 
 
Genotyping of NUP214/ABL1 pups (Genomic Purification Kit, Puregene) 
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Toes were lysed in 300µL cell lysis solution supplemented with 5µL 
Proteinase K over night at 55º. The next day, 1µL of RNaseA was added, 
tubes were vortexed and incubated for 1h at 37º. Proteins were precipitated 
with 100µL of protein precipitation solution, vortexed and centrifuged for 5min, 
full speed. The supernatant was transferred to another tube containing 300µL 
100% Isopropanol, vortexed and centrifuged again for 2min, full speed. The 
supernatant was discarded and the DNA pellet washed with 70% Ethanol. 
The pellet was air-dried, re-suspended in 50µL DNA hydration solution, 
incubated for 1h at 65º and left over night at room temperature. 
 
The PCR was pipetted as follows (for 1 tube): 
 2.5µL  PCR reaction Buffer 
 1µL  dNTPs (10µM) 
 1µL  forward primer (15µM) 
 1µL  reverse primer (15µM) 
 1.5µL  MgCl2 
 0.5µL  Taq polymerase 
 16.5µL ddH2O 
 1µL  DNA 
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The PCR program used was: 
 95º  5’ 
 95º  1’ 
 60º  1’   35 cycles 
 72º  1’15 
 72º  5’ 
 4º  ∞ 
 
Breeding of the NUP214/ABL1 mice 
The breedings were made in our mouse facility. NUP214/ABL1-positive 
males were bread with two wild type B6 females and NUP214/ABL1-positive 
females with one wild type B6 male. 
 
Control of transgene expression in NUP214/ABL1mice 
Mice were sacrificed in a CO2 chamber. Bone marrow, spleen and 
thymus were isolated in order to make cell suspensions. Erythrocytes were 
removed with RBC Lysis Buffer. Cell pellets were resuspended in 1mL of 
Trizol and homogenized. RNA was isolated following the Trizol protocol and 
cDNA was synthetized using the High capacity cDNA Reverse Transcription 
Kit (Applied Biosystems). Amplification of the NUP214/ABL1 fragment was 
done following the genotyping PCR. 
 
Blood counds 
 NUP214/ABL1 mice were bled into EDTA-coated tubes, the blood was 
diluted 1:1 in 0.9% NaCl solution and brought to the hematology lab from the 
Univeristy Hospital for analysis. 
 
Thymus status 
 Thymi from NUP214/ABL1 and WT B6 mice were isolated and single 
cell suspensions were done. Cells were stained with different antibody 
combinations for CD4, CD8 and TCRβ and analyzed with a BD FACSAria. 
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NUP214/ABL1 plasmid copy number determination 
 Genomic DNA from one transgenic mouse of each line and from a WT 
B6 mouse (20ng) were used as templates for RT-PCR using the Power SYBR 
Green Mastermix (Applied Biosystems) on an ABI Prism 7700 sequence 
detection system (Applied Biosystems). The experiment was performed 
following the protocole from Ralph Tiedt (Tiedt, 2008). 
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